

Inhaltsverzeichnis

Vorworte	1–2
Inhaltsverzeichnis	1–46
Abkürzungen	1–4

1 Nationale Richtlinien

1.0	Nationale Richtlinien – Einführung	1–3
	DE – Arzneimittel-Prüfrichtlinien	
1.1	Allgemeine Verwaltungsvorschrift zur Anwendung der Arzneimittelprüfrichtlinien (Oktober 2004)	1–55
1.2	Allgemeine Verwaltungsvorschrift zur Registrierung homöopathischer Arzneimittel zur Anwendung bei Tieren (Oktober 2004)	1–10
1.3	Verordnung zur Anwendung der Arzneimittelprüfrichtlinien, soweit es sich um Arzneimittel handelt, die zur Anwendung bei Tieren bestimmt sind, und zur Ablösung der Allgemeinen Verwaltungsvorschrift zur Anwendung der Tierarzneimittelprüfrichtlinien (Tierarzneimittel-Prüfrichtlinienverordnung – TamPV) (Februar 2010)	1–2
	DE – Andere nationale Vorschriften	
1.5	Verordnung über die Anwendung der Guten Herstellungspraxis bei der Herstellung von Arzneimitteln und Wirkstoffen und über die Anwendung der Guten fachlichen Praxis bei der Herstellung von Produkten menschlicher Herkunft (Arzneimittel- und Wirkstoffherstellungsverordnung – AMWHV) (Februar 2013)	1–44
1.6	Allgemeine Verwaltungsvorschrift zur Durchführung des Arzneimittelgesetzes (AMGwV) (März 2006)	1–13

DE – Klinische Prüfungen	
1.10	Verordnung über die Anwendung der Guten Klinischen Praxis bei der Durchführung von klinischen Prüfungen mit Arzneimitteln zur Anwendung am Menschen (GCP-Verordnung – GCP-V) (Oktober 2012) 1–21
1.13	Bekanntmachung über die Zulassung, Nachzulassung und Registrierung von Arzneimitteln (Empfehlungen der Kommission D nach § 25 Abs. 6 und Abs. 7 des Arzneimittelgesetzes zur Planung und Durchführung homöopathischer Arzneimittelprüfungen) (November 1998) 1–5
1.14	Kriterien für Erkenntnismaterial zu klinischen Indikationen in der Homöopathie (Oktober 2002) 1–5
1.18	Empfehlung über die Mindestanforderungen an die pharmakologisch-toxikologische Prüfung als Voraussetzung für den Beginn der klinischen Prüfung onkologischer Arzneimittel bei Menschen (Juni 1988) 1–3
1.19	Bekanntmachung einer Empfehlung über die Mindestanforderungen an die pharmakologisch-toxikologische Prüfung als Voraussetzung für den Beginn der klinischen Prüfung von Arzneimitteln gegen HIV-Infektionen und AIDS bei Menschen (Oktober 1991) 1–6
1.20	Prüfung von chemischen Desinfektionsmitteln auf Wirksamkeit gegen Viren in der Humanmedizin (August 2008) 1–19
1.21	Aufnahme von Desinfektionsmitteln und -verfahren in die vom Robert Koch-Institut gemäß § 10c BSeuchG aufzustellende Liste geprüfter und anerkannter Desinfektionsmittel und -verfahren (Dezember 1995) 1–3
1.25	Stabilitätsprüfung bei nach homöopathischen Verfahrenstechniken hergestellten Arzneimitteln (Juni 2006) 1–5
1.30	Empfehlung zur Verwendung von Ethylenoxid (1986) 1–2
1.31	Empfehlungen zu Ausgangsstoffen mit Ethylenoxid (April 1988).... 1
1.35	Mitteilung des BfArM zu Blutegeln in der Humanmedizin – Leitlinie zur Sicherung von Qualität und Unbedenklichkeit – (Juni 2009) 1–9
1.41	Bewertung fixer Kombinationen homöopathischer Einzelmittel – Bekanntmachung über die Zulassung von Arzneimitteln und die Verlängerung von Zulassungen nach § 105 des Arzneimittelgesetzes (Bewertungskriterien der Kommission D nach § 25 Abs. 6 und 7 des Arzneimittelgesetzes für fixe Kombinationen homöopathischer Einzelmittel) (April 1997) 1–5
1.42	Beurteilungskriterien für fixe Arzneimittelkombinationen bei Tierarzneimitteln (Februar 1987) 1–2
1.47	Bekanntmachung des BfArM über die Registrierung, Zulassung und Nachzulassung von Arzneimitteln – Duftstoff Moschus Ambrette – (Dezember 1997) 1–2

1.48	Bekanntmachung zu Maßnahmen zur Verminderung der Kontamination von parenteralen Arzneimitteln durch Asbest (November 1993)	1–5
1.49	Bekanntmachung zur Möglichkeit des Ersatzes der Prüfung auf Pyrogene durch die Prüfung auf Bakterien-Endotoxine nach DAB 10 (Parenteralie; Prüfung auf Reinheit) (November 1992).....	1–5
1.51	Überwachung von Heilwasserbetrieben und Heilquellen nach § 64 des Arzneimittelgesetzes (November 2007)	1–6
1.59	Herstellung applikationsfertiger Zytostatikallösungen in Apotheken – Zweck und Anwendungsbereich (Mai 1998)	1–13
DE – Blutzubereitungen		
1.60	Bekanntmachung der Richtlinien zur Gewinnung von Blut und Blutbestandteilen und zur Anwendung von Blutprodukten (Hämotherapie) gemäß §§ 12 und 18 des Transfusionsgesetzes (TFG) (Mai 2010)	1–78
1.62	Verminderung des Risikos der Übertragung von hämatogenen Viren bei Arzneimitteln, die durch Fraktionierung aus Plasma humanen Ursprungs hergestellt werden – Bekanntmachung über Maßnahmen zur Abwehr von Arzneimittelrisiken (August 1994).....	1–5
1.63	Verminderung des Risikos der Übertragung von Viren durch Arzneimittel, die durch Fraktionierung aus Plasma humanen Ursprungs hergestellt werden (August 1995)	1–2
1.64	Bekanntmachung über die Ergebnisse des Stufenplanverfahrens zur Verminderung des Risikos von Hepatitis B-, Hepatitis C- und HIV-Infektionen bei Empfängern von Erythrozytenkonzentraten (Februar 1998)	1–7
1.65	Bekanntmachung über die Abwehr von Arzneimittelrisiken – Verminderung des Risikos von Hepatitis C Virus-Kontaminationen in Thrombozytenkonzentraten (Juni 1998)	1–7
1.66	Bekanntmachung über die Zulassung und Registrierung von Humanarzneimitteln sowie über die Sicherheit verkehrsfähiger Humanarzneimittel (Vollblut, zelluläre Blutkomponenten und Gefrorenes Frischplasma sowie Arzneimittel aus humanen Geweben und homöopathische Arzneimittel humanen Ursprungs) – Abwehr von Arzneimittelrisiken, Stufe II – (September 2001).....	1–5
1.67	Bekanntmachung über die Zulassung und Registrierung von Humanarzneimitteln sowie über die Sicherheit von verkehrsfähigen Humanarzneimitteln – Abwehr von Arzneimittelrisiken, Stufe II – (Humanarzneimittel, die unter Verwendung von Blut oder Gewebe vom Menschen hergestellt werden) (Januar 1999)	1–4
1.68	Bekanntmachung über die Ergebnisse des Stufenplanverfahrens zur Verminderung des Risikos von Hepatitis-C-Virus-Kontaminationen in mittels Plasmapherese hergestelltem gefrorenen Frischplasma (September 1999).....	1–5

1.69	Abwehr von Arzneimittelrisiken – Bescheid über die Anordnung des Ausschlusses von Blutspenden zur Verhinderung einer möglichen Übertragung des West-Nil-Virus durch zelluläre Blutprodukte oder gefrorenes Frischplasma (September 2003)	1–5
1.70	Abwehr von Arzneimittelrisiken; Anordnung von Auflagen zu den Zulassungen für zelluläre Blutkomponenten und gefrorenen Frischplasmen (September 2008)	1–3
1.71	Bekanntmachung über die Zulassung von Arzneimitteln – Abwehr von Arzneimittelrisiken Stufe II – Verminderung des Risikos von A/H1N1-Infektionen durch zelluläre Blutprodukte und therapeutische Einzelplasmen (April 2009)	1–3
1.80	Bioäquivalenz-Monographie-Glyceroltrinitrat (GTN) (Dezember 1992)	1–9
1.81	Bioverfügbarkeit/Bioäquivalenz – Bekanntmachung über die Zulassung nach § 21 des Arzneimittelgesetzes (Bioverfügbarkeit/Bioäquivalenz) (Dezember 2002)	1–3
1.100	Leitlinien des BVL zur Gewinnung, Lagerung, Transport und Verabreichung von Blut und Blutprodukten im Veterinärbereich (Oktober 2010)	1–22
	DE – Arbeitskreis Blut	
1.150	Mitteilungen des Arbeitskreises Blut – Einführung	1–6
1.151	Sitzung vom 15.11.1993 (Aufwandsentschädigung für Blut- und Plasmaspender/Ausschluß von Drogenabhängigen aus der Spenderpopulation/Weitergabe von Daten HIV-positiver Spender an andere Blut- und Plasmaspendendienste)	1–2
1.152	Sitzungen am 15.11.1993 und am 24.1.1994 (Effiziente behördliche Kontrolle von Blutspende- und Plasmaspender-Institutionen/Begrenzung der Poolgröße bei der Verarbeitung von Blutplasma/Bewertung des HIV–1-p24-Antigen-Tests bei Blut und Plasmaspenden)	1–2
1.153	Sitzung am 14.3.1994 (Quarantänelagerung von durch frequente Plasmapherese gewonnenem Frischplasma/Anforderungen an Leiter von Blut- und Plasmaspendeeinrichtungen/Chargendokumentation für Albumin/Empfehlungen zur Eigenblutspende/Stellungnahme zur gerichteten Blutspende und Verwandtenspende)	1–3
1.154	Sitzung am 14.3.1994 (Quarantänelagerung von Plasma für die Fraktionierung)	1
1.155	Sitzung am 6.5.1994 (Minderung des Infektionsrisikos bei Blut und Blutprodukten durch optimiertes Screening von Spendern/Chargendokumentation bei der Anwendung von rekombinantem Faktor VIII/Zehn-Punkte-Empfehlung zur Etablierung eines koordinierten Meldewesens)	1–4
1.156	Sitzung am 14.7.1994 (Nutzung von PPSB-Präparat Beriplex nur bei vitaler Indikation)	1

1.157	Sitzung am 19.9.1994 (Verringerung des Übertragungsrisikos von Hepatitis B durch Testung auf Anti-HBc-Antikörper/Kennzeichnung von Blutprodukten zur Erleichterung der Chargendokumentation beim Anwender/Empfehlungen der Ad-hoc-Kommission des Arbeitskreises Blut zum Rückverfolgungsverfahren (look back) für Einzelspender und Kleinpools-Blutpräparate/Mindestvoraussetzungen für Eigenherstellung)	1–9
1.158	Sitzung vom 9.5.1995 (Verhinderung von bakterieller Kontamination bei Blutkonserven)	1–2
1.159	Sitzung vom 19.6.1995 (Empfehlungen zum Vorgehen bei reaktiven Screeningtesten auf HIV- oder HCV-Antikörper bzw. HBV-surface-Antigen bei Blut- und Plasmaspenden/Empfehlungen zu Bestellung und Aufgaben von Transfusionsverantwortlichen, Transfusionsbeauftragten, Transfusionskommissionen und Arbeitskreisen für Hämotherapie/Verwerfen von nicht verwendeten Eigenblut-Spenden und Ablehnung gerichteter Spenden)	1–6
1.160	Sitzung vom 1.9.1995 (Verbesserung von Screeningtesten für den Nachweis von Infektionserregern und Risikoabwehr/Verantwortlichkeit von fort- und weitergebildeten Ärzten für transfusionsrelevanten Immunhämatologie)	1–2
1.161	Sitzung vom 24.10.1995 (Hyperimmunplasma zur Herstellung von Hyperimmunglobulinen/Vorschläge zu Aufkommen und Verbrauch von Blutkomponenten und Plasmaderivaten mit dem Ziel der Selbstversorgung/Erhöhung der Sicherheit von Plasmapräparaten durch PCR-Testung)	1–5
1.162	Sitzung vom 23.1.1996 (Stellungnahme zu Rückrufaktionen wegen der Gefahr einer Übertragung der Creutzfeldt-Jakob-Erkrankung durch Blutprodukte)	1
1.163	Sitzung vom 14.5.1996 (V13) (Ergänzung zu Empfehlungen des Arbeitskreises Blut zum Vorgehen bei reaktiven Screeningtests auf HIV- oder HCV-Antikörper bzw. HBV-surface-Antigen bei Blut- und Plasmaspenden)	1–5
1.164	Sitzung vom 1.7.1996 (V 14) (Empfehlungen zur Rückverfolgung (look back) infektionsverdächtiger Plasmaspenden für Plasma zur Fraktionierung)	1–3
1.165	Sitzung vom 16.1.1997 (V 15) (Transfusionsmedizinische Ausbildung im Medizinstudium)	1
1.166	Sitzung vom 5.6.1997 (V 16) (Mindestanforderungen zur Sterilitätstestung von Blutkomponenten)	1–5
1.167	Sitzung vom 3.9.1997 (V 17) (Koordiniertes Meldewesen und Meldebögen: Ergänzung und Aktualisierung der Empfehlung/Empfehlung zu Nachuntersuchungsproben von therapeutischen Blutkomponenten und Rückstellproben von Plasmapools)	1–4
1.168	Sitzung vom 3.9.1997 (V 18) (Nukleinsäure-Nachweistechiken in der Transfusionsmedizin: Voraussetzungen)	1–6

1.169	Sitzung vom 19.3.1998 (V 19) (Nukleinsäure-Nachweistechiken in der Transfusionsmedizin: Voraussetzungen (Ergänzung)).....	1–2
1.170	Sitzung vom 16.9.1998 (V 20) (Testung von Blutspenden auf Hepatitis-C-Virus mit Nukleinsäure-Nachweis-Techniken).....	1
1.171	Sitzung vom 30./31.8.1999 (V 21) (Ergänzende Empfehlungen zur Testung von Blut- und Plasmaspenden und zum Rückverfolgungsverfahren)	1–6
1.172	Sitzung vom 16.11.1999 (V 22) (Empfehlung zum Meldewesen nach Transfusionsgesetz § 22 (Epidemiologische Daten))	1–8
1.173	Sitzung vom 16.11.1999 (V 23) (Empfehlung zum Meldewesen nach Transfusionsgesetz § 22 (Epidemiologische Daten): Erratum (V23))	1
1.174	Sitzung vom 8.11.2000 (V 24) (Verfahren zur Rückverfolgung (Look Back) gemäß § 19 Transfusionsgesetz)	1
1.175	Sitzung vom 1.3.2001 (V 25) (Empfehlung zur Einführung eines neuen Querschnittsbereichs mit Pflichtveranstaltung „ <i>Transfusionsmedizin mit Hämostaseologie</i> “ im Rahmen der Novellierung der Approbationsordnung)	1–2
1.176	Sitzung vom 15./16.10.2001 (V 26) (Zur europäischen Diskussion über die Aufwandsentschädigung für Blut- und Plasmaspender)	1
1.177	Sitzung vom 26.6.2002 (V 27) (Einführung des „Predonation Sampling“)	1
1.178	Sitzung vom 6.11.2002 (V 28) (Reduzierung des Zeitraums der Quarantänelagerung für gefrorenes Frischplasma (GFP) von 6 Monaten auf 4 Monate)	1
1.179	Sitzung vom 6.3.2003 (V 29) (Studentische Ausbildung in Transfusionsmedizin und Hämostaseologie (Hämotherapie))	1–2
1.180	Sitzung vom 1.10.2003 (V 30) (Verzicht auf die Bestimmung der Alanin-Aminotransferase (ALT) als Freigabekriterium für Blutkomponenten zur Transfusion und Plasma zur Fraktionierung)	1–2
1.181	Sitzung vom 17.3.2005 (V 31) (Erhöhung der Sicherheit von zellulären Blutkomponenten und quarantänelagertem Frischplasma durch Untersuchung der Blut- und Plasmaspenden auf Antikörper gegen das Hepatitis-B-Core-Antigen (Anti-HBc))	1–4
1.182	Sitzung vom 17.3.2005 (V 32) (Aktuelle Empfehlungen zur autologen Hämotherapie).....	1–4
1.183	Sitzung vom 11.1.2006 (V 33) (Vorgehensweise bei Variante Creutzfeldt-Jakob-Krankheit (vCJK) im Zusammenhang mit Blut, Plasma und Blutprodukten).....	1–5
1.184	Sitzung vom 14.6.2006 (V 34) (Verfahren zur Rückverfolgung (Look Back) (gemäß § 19 Transfusionsgesetz))	1–15
1.185	Sitzung vom 11.10.2006 (V 35) (Verfahren zur Rückverfolgung (Look Back) (gemäß § 19 Transfusionsgesetz) vom 14.06.2006)	1–2
1.186	Sitzung vom 1.10.2007 (V 36) (Verwechslungssichere Dokumentation durch einheitlichen Kennzeichnungscode für Blutkomponenten in Deutschland)	1

1.187	Sitzung vom 9.6.2008 (V 37) (Meldung von Spendern mit Antikörpern gegen das Hepatitis-B-Core-Antigen (Anti-HBc))	1–2
1.188	Sitzung vom 9.6.2008 (V 38) (Festlegung der Haltbarkeitsfrist von Thrombozytenkonzentraten mit dem Ziel der Reduktion lebensbedrohlicher septischer Transfusionsreaktionen durch bakterielle Kontamination)	1
1.188a	Sitzung vom 9.6.2008 (V 38) (Reduktion des Septikämierisikos bei der Anwendung von Thrombozytenkonzentraten)	1–6
1.189	Sitzung vom 9.1.2009 (V 39) (Maßnahmen zur Vermeidung der transfusionsinduzierten Lungeninsuffizienz (TRALI))	1–2
1.189a	Sitzung vom 30.11.2009 (V 40) (Aufrechterhaltung der Blutversorgung bei einer Influenza-Pandemie)	1–2
1.189b	Sitzung vom 7.6.2010 (V 41) (Verwendung eines einheitlichen Fragebogens für Blut- und Plasmaspender)	1–2
1.189c	Sitzung vom 7.11.2012 (V 42) (Aktualisierung der Voten 34 und 35 „Verfahren zur Rückverfolgung (Look Back) (gemäß § 19 Transfusionsgesetz)“ vom 14.06.2006 im Hinblick auf Hepatitis-B-Infektionen)	1–4
1.189d	Sitzung vom 7.11.2012 (V 43) (Mindestanforderungen an die mikrobiologische Kontrolle von Blutkomponenten zur Transfusion – Aktualisierung des Votums 16)	1–4
1.190	Arbeitskreis Blut: Bewertungen von Krankheitserregern, die durch Blut übertragen werden (Übersicht über alle Stellungnahmen)	1–3
1.190a	Bewertung von Krankheitserregern, die durch Blut übertragen werden (Februar 1998)	1–2
1.191	Humane T-Zell lymphotrope Viren Typ 1 und 2 (HTLV-I/-II) (November 1998)	1–13
1.192	Filtration von zellulären Blutpräparaten (September 1998)	1–5
1.193	Sitzung vom 2. Dezember 1998 (S3) (Stellungnahme zur Frage erhöhter Spendevolumina bei der Plasmapherese)	1
1.194	Sitzung vom 19. März 1998 (Was bedeutet die neue Variante der Creutzfeldt-Jakob-Krankheit für die Sicherheit von Blutprodukten?)	1–4
1.195	Stellungnahme: Yersinia enterocolitica (Juli 1999)	1–16
1.196	Stellungnahme: TT-Virus (Februar 2000)	1–6
1.197	Stellungnahme: Hepatitis-B-Virus (HBV) (März 2000)	1–16
1.199	Stellungnahme: Leukozytendepletion (November 2000)	1–2
1.199a	Stellungnahme: Hepatitis-C-Virus (HCV) (August 2003)	1–23
1.199b	Stellungnahme: Humanes Immunschwärevirus (HIV) (Mai 2003)	1–26
1.200	Stellungnahme: Arboviren – durch Anthropoden übertragbare Viren (September 2004)	1–17
1.201	Stellungnahme: Gerinnungsfaktorpräparat Haemate HS/P 1000 und Risiko der Variante Creutzfeldt-Jakob-Krankheit (Januar 2005)	1
1.203	Stellungnahme: Variante Creutzfeldt-Jakob-Krankheit (September 2005)	1–19

1.204	Stellungnahme: Beendigung der Spenderrückstellung nach Kontakt mit tot aufgefundenen Vögeln (Oktober 2006)	1
1.205	Stellungnahme: Influenzaviren (September 2007)	1–16
1.206	Stellungnahme: Arbobakterien (September 2007)	1–32
1.208	Stellungnahme: Malaria (Februar 2007)	1–26
1.209	Stellungnahme: Arboprotzoen (Februar 2008)	1–47
1.210	Stellungnahme: Risiko der Übertragung von vCJK (April 2009)	1–2
1.211	Stellungnahme: Versorgung mit Blutprodukten im Falle einer Influenza-Pandemie (September 2009)	1–24
1.212	Stellungnahme: Blutversorgung bei Notfällen in Einrichtungen der Krankenversorgung (März 2011)	1
1.213	Stellungnahme: Sicherheit von Blut und Blutprodukten angesichts aktueller Berichte über die Übertragbarkeit der Alzheimer-Krankheit im Tierexperiment (S11) (Juni 2012)	1–2
1.214	Stellungnahme: Befristete Rückstellung von der Blutspende bei Personen mit sexuellem Risikoverhalten (S12) (März 2013)	1–2
1.215	Stellungnahme zur Zulassung von Spendewilligen mit körperlichen und/oder geistigen Einschränkungen (Februar 2014)	1–2
1.216	Stellungnahme zur erlaubnisfreie Gewinnung und Anwendung von Blut im Rahmen der maschinellen Autotransfusion (MAT) (S 14) (Februar 2014)	1–3
1.217	Stellungnahme zur Bewertung von Apherese- und Pool-Thrombozytenkonzentraten (S 15) (März 2015)	1–4
DE – Tierarzneimittel und Tierschutz		
1.301	Quantitative Bestimmung der Sicherheit individueller Tierarzneimittel und ggf. der Anforderungen an noch durchzuführende risikomindernde Maßnahmen (November 1995)	1–21
1.310	Bekanntmachung über die Zulassung und Verlängerung der Zulassungen nach § 31 bzw. § 105 des Arzneimittelgesetzes (AMG) (Verfahrensweise bei Arzneimittel-Vormischungen) (Dezember 1998)	1–2
1.400	Herstellung und Prüfung von Arzneimitteln unter Tierschutzgesichtspunkten	1
1.401	Die Produktion monoklonaler Antikörper unter Tierschutzgesichtspunkten (1997)	1
1.410	Die Erzeugung und Zucht transgener Mäuse und Ratten unter Tierschutzgesichtspunkten (1997)	1–9
1.420	Empfehlungen zur tierschutzrechtlichen Bewertung von Eingriffen und Behandlungen an Wirbeltieren bei der Prüfung von Tierarzneimitteln nach der Richtlinie 92/18/EWG der Kommission vom 20. März 1992 (1997)	1–5
1.600	Abwehr von Arzneimittelrisiken, Stufe II: Körperflüssigkeiten (Dezember 2000)	1–8
1.601	Abwehr von Arzneimittelrisiken, Stufe II – Ergänzung – (Januar 2001)	1–4

1.650	Abwehr von Arzneimittelrisiken, Stufen II: TSE (Januar 2001)	1–3
1.651	Bekanntmachung zur Verwendung von Gelatine in Arzneimitteln (Januar 2001)	1–2
1.680	Leukozytendepletion von zellulären Blutprodukten zur Transfusion – Ergebnisse des Stufenplanverfahrens (August 2000)	1–6
2	EU – Richtlinien und Leitlinien (hum und vet)	
2.0	Europäische Union – Einführung.....	1–4
	EU – Richtlinien für Human- und Tierarzneimittel (hum und vet)	
2.1	Directive 2001/83/EC of the European Parliament and of the Council on the Community Code Relating to Medicinal Products for Human Use (November 2002 – consolidated version)	1–172
2.2	Richtlinie 2002/98/EG zur Festlegung von Qualitäts- und Sicherheitsstandards für die Gewinnung, Testung, Verarbeitung, Lagerung und Verteilung von menschlichem Blut und Blutbestandteilen und zur Änderung der Richtlinie 2001/83/EG (Januar 2003)	1–21
2.2a	Commission Directive 2004/33/EC Implementing Directive 2002/98/EC of the European Parliament and of the Council as Regards Requirements for Blood and Blood Components (March 2004)	1–24
2.2b	Commission Directive 2005/61/EC Implementing Directive 2002/98/EC of the European Council as Regards Traceability Requirements and Notification of Serious Adverse Reactions and Events (September 2005)	1–12
2.4	Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 2014 on Clinical Trials on Medicinal Products for Human Use, and Repealing Directive 2001/20/EC (April 2014)	1–94
2.5	Commission Delegated Regulation (EU) No 357/2014 of 3 February 2014 Supplementing Directive 2001/83/EC and Regulation (EC) No 726/2004 as Regards Situations in Which Post-Authorisation Efficacy Studies May be Required (February 2014)	1–5
2.7	Richtlinie 2005/28/EG der Kommission zur Festlegung von Grundsätzen und ausführlichen Leitlinien der guten klinischen Praxis für zur Anwendung beim Menschen bestimmte Prüfpräparate sowie von Anforderungen für die Erteilung einer Genehmigung zur Herstellung oder Einfuhr solcher Produkte (April 2005)	1–12
2.8	Directive 2004/23/EC of the European Parliament and of the Council on Setting Standards of Quality and Safety for the Donation, Procurement, Testing, Processing, Preservation, Storage and Distribution of Human Tissues and Cells (March 2004)	1–18

2.9	Commission Directive 2006/17/EC Implementing Directive 2004/23/EC of the European Parliament and of the Council as Regards Certain Technical Requirements for the Donation, Procurement and Testing of Human Tissues and Cells (February 2006)	1–17
2.9a	Commission Directive 2006/86/EC Implementing Directive 2004/23/EC of the European Parliament and of the Council as Regards Traceability Requirements, Notification of Serious Adverse Reactions and Events and Certain Technical Requirements for the Coding, Processing, Preservation, Storage and Distribution of Human Tissues and Cells (October 2006)	1–23
2.10	Directive 2001/82/EC of the European Parliament and of the Council on the Community Code Relating to Veterinary Medicinal Products (July 2009 – konsolidiert)	1–122
	EU – Leitlinien für Humanarzneimittel (hum)	
2.25	EU-Leitlinien für Humanarzneimittel – Einführung	1–2
2.26	Procedure for European Union Guidelines and Related Documents within the Pharmaceutical Legislative Framework (March 2009)	1–17
2.27a	Guideline on Similar Biological Medicinal Products Containing Monoclonal Antibodies – Non-clinical and Clinical Issues (May 2012).....	1–17
2.28	Guideline on the Definition of a Potential Serious Risk to Public Health in the Context of Article 29 (1) and (2) of Directive 2001/83/EC (March 2006)	1–4
2.29	Guideline on the Definition of a Potential Serious Risk to Human or Animal Health or for the Environment in the Context of Article 33(1) and (2) of Directive 2001/82/EC (March 2006)	1–6
2.30	Evaluation of Control Samples in Nonclinical Safety Studies: Checking for Contamination with the Test Substance (March 2005)	1–3
2.31	Non-Clinical Investigation of the Dependence Potential of Medicinal Products (March 2006).....	1–12
2.31a	Guideline on the Development of Medicinal Products for the Treatment of Alcohol Dependence (February 2010).....	1–17
2.32	Non-Clinical Documentation for Mixed Marketing Authorisation Applications (October 2005).....	1–3
2.35	Adjuvants in Vaccines for Human Use (January 2005)	1–16
2.36	Explanatory Note on Immunomodulators for the Guideline on Adjuvants in Vaccines for Human Use (July 2006).....	1
2.40	Guideline on the Need for Non-Clinical Testing in Juvenile Animals of Pharmaceuticals for Paediatric Indications (January 2008)..	1–9
2.42	Guideline on the Specification Limits for Residues of Metal Catalysts or Metal Reagents (February 2008).....	1–34
2.45	Guideline on Compassionate Use of Medicinal Products, pursuant to Article 83 of Regulation (EC) No 726/2004 (July 2007).....	1–8
2.47	Ethical Considerations for Clinical Trials on Medicinal Products with the Paediatric Population (2007).....	1–39

2.50	Choice of the Non-Inferiority Margin (July 2005)	1–13
2.51	Guideline on the Clinical Investigation of the Pharmacokinetics of the Therapeutic Proteins (January 2007)	1–12
2.52	Guideline on the Use of Pharmacogenetic Methodologies in the Pharmacokinetic Evaluation of Medicinal Products (January 2012)	1–22
2.52a	Guideline on Reporting the Results of Population Pharmacokinetic Analyses (June 2007)	1–12
2.53	Evaluation of the Pharmacokinetics of Medicinal Products in Patients with Impaired Renal Function (June 2004)	1–11
2.54	Evaluation of the Pharmacokinetics of Medicinal Products in Patients with Impaired Hepatic Function (February 2005)	1–10
2.55	Guideline on Clinical Development of Fixed Combination Medicinal Products (February 2009)	1–8
2.55a	Guideline on the Clinical Assessment of Fixed Combinations of Herbal Substances/Herbal Preparations (January 2006)	1–6
2.55b	Guideline on the Non-Clinical Development of Fixed Combinations of Medicinal Products (January 2008)	1–6
2.56	Questions and Answers Document on the Clinical Development of Fixed Combinations of Drugs Belonging to Different Therapeutic Classes in the Field of Cardiovascular Treatment and Prevention (June 2005)	1–3
2.57	Eignung von Blut- und Plasmaspendern und das Screening von Blutspenden in der Europäischen Gemeinschaft (Juni 1998)	1–17
2.58	Replacement of Animal Studies by in vitro Models (February 1997)	1–6
2.59	Guideline on Repeated Dose Toxicity (March 2010)	1–9
2.61	Carcinogenic Potential (July 2002)	1–7
2.62	Guideline on Carcinogenicity Evaluation of Medicinal Products for the Treatment of HIV Infection (December 2007)	1–7
2.63	Guideline on Medicinal Gases (July 2008)	1–13
2.66	Guideline on the Investigation of Bioequivalence (January 2010/ November 2011)	1–44
2.67	Compilation of Individual Product-Specific Guidance on Demonstration of Bioequivalence (April 2015)	1–14
	EU – Qualität (hum)	
2.68	Manufacture of the Finished Dosage Form (September 1995)	1–6
2.68a	Annex: Start of Shelf Life of the Finished Dosage Form (May 2001)	1
2.69	Quality of Oral Modified Release Products (March 2014)	1–15
2.70	Quality of Transdermal Patches (October 2014)	1–25
2.71a	Decision Trees for the Selection of Sterilisation Methods (Annex to Note for Guidance on Development Pharmacuetics) (February 1999)	1–3
2.71b	Development Pharmaceutics for Biotechnological and Biological Products (Annex to Note for Guidance on Development Pharmaceutics) (October 1999)	1–4

2.72	Specifications and Control Tests on the Finished Product (December 1991)	1–10
2.73	Guideline on Real Time Release Testing (March 2012)	1–10
2.73a	Declaration of Storage Conditions: A: In the Product Information of Medicinal Products B: For Active Substances (April 2003)	1–3
2.73c	Stability Testing of Existing Active Substances and Related Finished Products (December 2003)	1–19
2.73d	Stability Testing for Applications for Variations to a Marketing Authorisation (March 2014)	1–16
2.73e	Guideline on Quality of Combination Herbal Medicinal Products/Traditional Herbal Medicinal Products (June 2008)	1–11
2.74	Guideline on Quality of Herbal Medicinal Products/Traditional Herbal Medicinal Products (September 2011)	1–12
2.74a	Specifications: Test Procedures and Acceptance Criteria for Herbal Substances, Herbal Preparations and Herbal Medicinal Product/Traditional Herbal Medicinal Products (April 2011)	1–24
2.74b	Good Agricultural and Collection Practice for Starting Materials of Herbal Origin (January 2006)	1–9
2.74c	Non-Clinical Documentation for Herbal Medicinal Products in Applications for Marketing Authorisation (Bibliographical and Mixed Applications) and in Applications for Simplified Registration (July 2006)	1–7
2.74d	Assessment of Clinical Safety and Efficacy in the Preparation of Community Herbal Monographs for Well-Established and of Community Herbal Monographs/Entries to the Community List for Traditional Herbal Medicinal Products/Substances/Preparations (September 2006)	1–14
2.74e	Guideline on Selection of Test Materials for Genotoxicity Testing for Traditional Herbal Medicinal Products/Herbal Medicinal Products (November 2009)	1–6
2.75	Quality of Water for Pharmaceutical Use (May 2002)	1–7
2.77	Production and Quality Control of Cytokine Products Derived by Biotechnological Processes (February 1990)	1–11
2.78	Virus Validation Studies: The Design, Contribution and Interpretation of Studies Validating the Inactivation and Removal of Viruses (March 1996)	1–14
2.78a	Contribution to Part II of the Structure of the Dossier for Applications for Marketing Authorization – Viral Safety Studies (December 1994)	1–6
2.79	Note for Guidance on Minimising the Risk of Transmitting Animal Spongiform Encephalopathy Agents via Human and Veterinary Medicinal Products (March 2011)	1–26
2.79a	Explanatory Note for Medicinal Products for Human Use on the Scope of the Guideline (February 2001)	1–3
2.79b	Gelatin for Use in Pharmaceuticals: Explanatory Note on the Manufacture of Gelatin (December 2000)	1

2.79c	Lactose Prepared Using Calf Rennet: Risk Assessment in Relationship to Bovine Spongiform Encephalopathies (BSE) (February 2002)	1
2.79d	Evaluation of Bovine Spongiform Encephalopathies (BSE)-risk via the Use of Materials of Bovine Origin in or During the Manufacture of Vaccines (February 2001)	1–2
2.79e	Adventitious Agent Safety of Urine-Derived Medicinal Products (May 2015)	1–6
2.79f	Use of Near Infrared Spectroscopy by the Pharmaceutical Industry and the Data Requirements for New Submissions and Variations (January 2014)	1–29
	EU – Biotechnologische Arzneimittel (hum)	
2.80	Similar Biological Medicinal Products (October 2014)	1–6
2.80a	Guideline on Immunogenicity Assessment of Biotechnology-Derived Therapeutic Proteins (December 2007)	1–23
2.80b	Guideline on Immunogenicity Assessment of Monoclonal Antibodies Intended for In Vivo Clinical Use (May 2012)	1–11
2.81	Production and Quality Control of Medicinal Products Derived by Recombinant DNA Technology (Revision 1994)	1–10
2.81b	Guideline on Non-clinical and Clinical Development of Similar Biological Medicinal Products Containing Recombinant Erythropoietins (Revision) (March 2010)	1–8
2.81c	Annex to Guideline on Similar Biological Medicinal Products Containing Biotechnology-Derived Proteins as Active Substance: Non-Clinical and Clinical Issues (February 2006)	1–6
2.81d	Annex to Guideline on Similar Biological-Derived Proteins as Active Substance: Non-Clinical and Clinical Issues (February 2006)	1–6
2.81e	Non-Clinical and Clinical Development of Similar Biological Medicinal Products Containing Recombinant Human Insulin and Insulin Analogues (February 2015)	1–11
2.81f	Guideline on Comparability of Biotechnology-Derived Medicinal Products after a Change in the Manufacturing Process (July 2007) ..	1–11
2.81g	Guideline on Similar Biological Medicinal Products Containing Low-Molecular-Weight-Heparins (March 2009)	1–8
2.81h	Non-clinical and Clinical Development of Similar Biological Medicinal Products Containing Recombinant Human Follicle Stimulating Hormone (r-hFSH) (February 2013)	1–7
2.81i	Similar Biological Medicinal Products Containing Interferon Beta (February 2013)	1–8
2.82	Similar Biological Medicinal Products Containing Biotechnology-Derived Proteins as Active Substance: Quality Issues (Rev. 1) (May 2014)	1–9
2.82a	Similar Biological Medicinal Products Containing Biotechnology-Derived Proteins as Active Substance: Non-clinical and Clinical Issues (December 2014)	1–13

2.83	Production and Quality Control of Animal Immunoglobulins and Immunosera for Human Use (July 2002).....	1–13
2.83a	Use of Bovine Serum in the Manufacture of Human Biological Medicinal Products (May 2013)	1–8
2.84	Non-Clinical Local Tolerance Testing of Medicinal Products (Revision February 2001)	1–7
2.84a	Development of Vaccinia Virus Based Vaccines Against Smallpox (June 2002).....	1–19
2.84b	Guideline on Dossier Structure and Content for Pandemic Influenza Vaccine Marketing Authorisation Application (December 2008).....	1–19
2.84c	Submission of Marketing Authorisation Applications for Pandemic Influenza Vaccines through the Centralised Procedure (March 2004)	1–11
2.85	Influenza Vaccines – Quality Module (25 April 2014)	1–36
2.85a	Pharmaceutical and Biological Aspects of Combined Vaccines (July 1998)	1–14
2.85b	Explanatory Note on the Withdrawal of the Note for Guidance on Harmonisation of Requirements for Influenza Vaccines and of the Core SmPC/PL for Inactivated Seasonal Influenza Vaccines (January 2014)	1–5
2.86	Preclinical Pharmacological and Toxicological Testing of Vaccines (December 1997)	1–6
2.86b	Validation of Immunoassay for the Detection of Antibody to Human Immunodeficiency Virus (Anti HIV) in Plasma Pools (September 2006).....	1–6
2.86c	Plasma-Derived Medicinal Products (Revision 3, January 2001; ergänzt October 2004).....	1–39
2.86d	Guideline on the Clinical Investigation of Human Normal Immunoglobulin for Intravenous Administration (IVIg) (July 2010)	1–14
2.86e	Clinical Investigation of Recombinant and Human Plasma-Derived Factor IX Products (May 2015)	1–21
2.86f	Guideline on the Clinical Investigation of Recombinant and Human Plasma-Derived Factor VIII Products (July 2011).....	1–22
2.86g	CHMP Position Statement on Creutzfeldt-Jakob Disease and Plasma-Derived and Urine-Derived Medicinal Products (June 2004)	1–18
2.86h	Investigation of Manufacturing Processes for Plasma-Derived Medicinal Products with Regard to vCJD Risk (October 2004).....	1–11
2.86i	Validation of Immunoassay for the Detection of Hepatitis B Virus Surface Antigen (HBsAg) in Plasma Pools (September 2006).....	1–6
2.86j	Guideline on the Replacement of Rabbit Pyrogen Testing by an Alternative Test for Plasma-Derived Medicinal Products (April 2009)	1–6
2.87	Guideline on Allergen Products: Production and Quality Issues (November 2008)	1–20
2.87a	Guideline on the Clinical Development of Products for Specific Immunotherapy for the Treatment of Allergic Diseases (November 2008)	1–14

2.88	Gene Therapy Products – Quality Aspects in the Production of Vectors and Genetically Modified Somatic Cells (December 1994) .	1–10
2.88a	Quality, Preclinical and Clinical Aspects of Gene Transfer Medicinal Products (April 2001).....	1–35
2.88b	Development and Manufacture of Lentiviral Vectors (May 2005)....	1–7
2.88c	Guideline on Non-Clinical Testing for Inadvertent Germline Transmission of Gene Transfer Vectors (November 2006).....	1–8
2.88d	Guideline on Quality, Non-Clinical and Clinical Aspects of Live Recombinant Viral Vected Vaccines (June 2010).....	1–18
2.89	Quality of Biological Active Substances Produced by Transgene Expression in Animals (May 2013)	1–11
2.89a	Guideline on the Quality of Biological Active Substances Produced by Stable Transgene Expression in Higher Plants (July 2008)	1–12
	EU – Klinische Prüfungen – Allgemein (hum)	
2.90a	Guideline on the Requirements for Quality Documentation Concerning Biological Investigational Medicinal Products in Clinical Trials (March 2012)	1–16
2.91	Inclusion of Appendices to Clinical Study Reports in Marketing Authorisation Applications (June 2004)	1–2
2.91a	Coordinating Investigator Signature of Clinical Study Reports (October 2001)	1
2.92	Guideline on Data Monitoring Committees (July 2005)	1–8
2.92a	Guideline on Missing Data in Confirmatory Clinical Trials (June 2010).....	1–15
2.93	Role of Pharmacokinetics in the Development of Medicinal Products in the Paediatric Population (June 2006).....	1–9
2.93a	Guideline on the Investigation of Medicinal Products in the Term and Preterm Neonate (June 2009).....	1–26
2.94a	Guideline on Strategies to Identify and Mitigate Risks for First-In-Human Clinical Trials with Investigational Medicinal Products (July 2007)	1–14
2.94b	Pharmacokinetic and Clinical Evaluation of Modified Release Dosage Forms (November 2014).....	1–47
2.94c	Adjustment for Baseline Covariates in Clinical Trials (February 2015)	1–11
	EU – Klinische Prüfungen – Therapeutische Klassen (hum)	
2.95a	Guideline on Clinical Development of Products for the Treatment of Cystic Fibrosis (October 2009).....	1–28
2.95b	Guideline on the Clinical Evaluation of Antifungal Agents for the Treatment and Prophylaxis of Invasive Fungal Disease (April 2010)	1–18
2.96	Clinical Investigation of Medicinal Products for the Treatment of Cardiac Failure (December 1999).....	1–13
2.96a	Clinical Investigation of Medicinal Products for the Treatment of Acute Heart Failure (May 2015).....	1–18

2.96b	Guideline on the Evaluation of Medicinal Products for Cardiovascular Disease Prevention (September 2008)	1–8
2.96c	Guideline on the Development of Medicinal Products for the Treatment of Smoking (December 2008)	1–12
2.96d	Guideline on the Evaluation of Drugs for the Treatment of Gastro-Oesophageal Reflux Disease (March 2011)	1–27
2.97	Guidelines on Antiarrhythmics (EMA Status as of November 1995)	1–7
2.97/1	Addendum to the Guideline on Antiarrhythmics on Atrial Fibrillation and Atrial Flutter (July 2010)	1–10
2.97a	Guideline on Clinical Investigation of Medicinal Products for the Treatment of Juvenile Idiopathic Arthritis (October 2006)	1–13
2.97b	Guideline on Clinical Investigation of Medicinal Products for the Treatment of Psoriatic Arthritis (December 2006)	1–12
2.97c	Guideline on Clinical Investigation of Medicinal Products Used in the Treatment of Osteoarthritis (January 2010)	1–14
2.98	Clinical Investigation of Medical Products in the Treatment and Prevention of Bipolar Disorder (April 2001)	1–10
2.98a	Guideline on the Development of New Medicinal Products for the Treatment of Crohn's Disease (July 2008)	1–11
2.98b	Guideline on Clinical Investigation of Immunosuppressants for Solid Organ Transplantation (July 2008)	1–17
2.99	Guideline on the Evaluation of Anticancer Medicinal Product in Man (December 2012)	1–57
2.99b	Guideline on Non-Clinical and Clinical Development of Medicinal Products for the Treatment of Nausea and Vomiting Associated with Cancer Chemotherapy (December 2006)	1–10
2.100	Guideline on Clinical Investigation of Medicinal Products in the Treatment of Epileptic Disorder (January 2010)	1–20
2.100a	Guideline on Clinical Investigation of Medicinal Products for the Treatment of Ankylosing Spondylitis (April 2009)	1–13
2.101	Guideline on Medicinal Products for the Treatment of Insomnia (February 2011)	1–22
2.101a	Guideline on the Development of Medicinal Products for the Treatment of Post-Traumatic Stress Disorder (PTSD) (July 2008)	1–11
2.102	Clinical Investigation of Medicinal Products Indicated for the Treatment of Social Anxiety Disorder (SAD) (January 2006)	1–12
2.102a	Clinical Investigation of Medicinal Products for the Prophylaxis of Venous Thromboembolic Risk in Non-Surgical Patients (June 2006)	1–9
2.102b	Clinical Investigation of Medicinal Products for Prevention of Venous Thromboembolism (VTE) in Patients Undergoing High VTE-Risk Surgery (May 2013)	1–18
2.102c	Clinical Investigation of Medicinal Products for Prevention of Stroke and Systemic Embolic Events in Patients with Non-Valvular Atrial Fibrillation (June 2014)	1–15

2.103	Clinical Investigations of Medicinal Products in the Treatment of Chronic Peripheral Arterial Occlusive Disease (April 2002)	1–16
2.103a	Clinical Investigation of Medicinal Products in the Treatment of Patients with Acute Respiratory Distress Syndrome (September 2006)	1–10
2.103b	Clinical Investigation of Medicinal Products for the Treatment of Sepsis (June 2006)	1–10
2.104	Guideline on the Clinical Development of Medicinal Products for the Treatment of HIV Infection (November 2008)	1–29
2.104a	Clinical Evaluation of Medicinal Products Intended for Treatment of Chronic Hepatitis B (February 2006)	1–26
2.104b	Guideline on the Clinical Evaluation of Direct Acting Antiviral Agents Intended for Treatment of Chronic Hepatitis C (April 2009)	1–14
2.105	Guideline on Clinical Trials with Haematopoietic Growth Factors for the Prophylaxis of Infection Following Myelosuppressive or Myeloablative Therapy (March 2007)	1–11
2.105a	Clinical Investigation of Medicinal Products for Treatment of Nociceptive Pain (November 2002)	1–11
2.105b	Guideline on the Clinical Investigations of Medicinal Products for the Treatment of Pulmonary Arterial Hypertension (October 2009) .	1–9
2.105c	Paediatric Addendum to CHMP Guideline on the Clinical Investigations of Medicinal Products for the Treatment of Pulmonary Arterial Hypertension (December 2011)	1–7
2.106	Guideline on Clinical Investigation of Medicinal Products in the Treatment of Hypertension (November 2010)	1–17
2.106a	Clinical Investigation of Medicinal Products in the Treatment of Lipid Disorders (December 2013)	1–16
2.106b	Paediatric Addendum to CHMP Guideline on Clinical Investigation of Medicinal Products in the Treatment of Lipid Disorders (September 2012)	1–6
2.107	Guideline on Clinical Investigation of Medicinal Products, Including Depot Preparations in the Treatment of Schizophrenia (September 2012)	1–24
2.107a	Clinical Investigation of Medicinal Products in the Treatment of Depression (May 2013)	1–20
2.107b	Clinical Investigation of Medicinal Products for the Treatment of Obsessive Compulsive Disorder (January 2005)	1–0
2.107c	Clinical Investigation of Medicinal Products Indicated for the Treatment of Panic Disorder (January 2005)	1–10
2.107d	Clinical Investigation of Medicinal Products Indicated for Generalised Anxiety Disorder (January 2005)	1–8
2.107e	Guideline on Clinical Investigation of Medicinal Products for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) (July 2010)	1–14

2.107f	Guideline On the Treatment of Premenstrual Dysphoric Disorder (PMDD) (July 2011)	1–18
2.108	Guideline on Clinical Evaluation of Medicinal Products Used in Weight Control (November 2007)	1–11
2.108a	Guideline on Clinical Evaluation of Medicinal Products Used in Weight Control Addendum on Weight Control in Children (July 2008)	1–6
2.109	Note for Guidance on Postmenopausal Osteoporosis in Women (January 2001)	1–10
2.109b	Clinical Investigation of Medicinal Products for Hormone Replacement Therapy of Oestrogen Deficiency Symptoms in Postmenopausal Women (October 2005)	1–11
2.110	Guideline on Medicinal Products for the Treatment of Alzheimer's Disease and other Dementias (July 2008)	1–23
2.110a	Clinical Investigation of Medicinal Products for the Treatment of Venous Thromboembolic Disease (December 1999).....	1–7
2.110b	Clinical Investigation of Plasma Derived Antithrombin Products (April 2002)	1–9
2.110d	Clinical Investigation of Plasma Derived Fibrin Sealant Haemostatic Products (July 2004)	1–6
2.110e	Clinical Investigation of Human Plasma Derived Von Willebrand Factor Products (November 2005).....	1–15
2.111	Guideline on Clinical Evaluation of New Vaccines (October 2006) .	1–23
2.111a	Guideline on Clinical Evaluation of New Vaccines – Annex: SPC Requirements (October 2006).....	1–5
2.112	Guideline on Clinical Investigation of Medicinal Products in the Treatment of Parkinson's Disease (June 2012).....	1–16
2.112a	Guideline on Clinical Medicinal Products Intended for the Treatment of Neuropathic Pain (January 2007)	1–11
2.113	Clinical Investigation of Anti-Anginal Medicinal Products in Stable Angina Pectoris (June 2006).....	1–9
2.113a	Guideline on Clinical Investigation of Medicinal Products for the Treatment of Migraine (January 2007)	1–12
2.114	Clinical Investigation of Medicinal Products for the Treatment of Multiple Sclerosis (March 2015)	1–20
2.114a	Clinical Investigation of Medicinal Products for the Treatment of Urinary Incontinence (June 2013)	1–20
2.114b	Guideline on Clinical Investigation of Medicinal Products in the Treatment of Chronic Obstructive Pulmonary Disease (COPD) (July 2012)	1–17
2.115	Guideline on Clinical Investigation of Medicinal Products in the Treatment or Prevention of Diabetes Mellitus (May 2002)	1–26
2.115a	Clinical Investigation of Medicinal Products for Treatment of Asthma (November 2002)	1–9
2.115b	Clinical Investigation of Medicinal Products Indicated for the Treatment of Psoriasis (November 2004).....	1–18

2.115c	Clinical Development of Medicinal Products for the Treatment of Allergic Rhino-Conjunctivitis (May 2012).....	1–9
2.116	Guideline on the Investigation of Drug Interactions (June 2012).....	1–70
2.117	Clinical Investigation of Steroid Contraceptives in Women (July 2005)	1–6
2.117a	Guideline on the Evaluation of Medicinal Products Indicated for Treatment of Bacterial Infections (December 2011).....	1–28
2.117b	Addendum to the Note of Guidance on Evaluation of Medicinal Products Indicated for Treatment of Bacterial Infections To Specifically Address the Clinical Development of New Agents to Treat Disease Due to Mycobacterium Tuberculosis (January 2010)	1–16
2.117c	Addendum to the Guideline on the Evaluation of Medicinal Products Indicated for Treatment of Bacterial Infections (October 2013)	1–23
2.118	Clinical Investigation of Human Anti-D Immunoglobulin for Intravenous and/or Intramuscular Use (September 2007)	1–7
2.119a	Clinical Investigation of Human Normal Immunglobulin for Subcutaneous and Intramuscular Use (July 2002)	1–7
2.120	Guideline on Radiopharmaceuticals (November 2008).....	1–11
2.122	Guideline on Development, Production, Characterisation and Specifications for Monoclonal Antibodies and Related Products (December 2008)	1–11
2.124	Paediatric Addendum to the Note for Guidance on the Clinical Investigation on Medicinal Products in the Treatment of Hypertension (February 2015).....	1–11
2.125	The Use of Ionizing Radiation in the Manufacture of Medicinal Products (December 1991)	1–5
2.130	Guideline on Clinical Evaluation of Diagnostic Agents (July 2009).	1–20
2.150	Summary of Requirements for Active Substances in the Quality Part of the Dossier (June 2004).....	1–9
2.151	Chemistry of New Active Substances (December 2003).....	1–11
2.152	Investigation of Chiral Active Substances (1993)	1–9
2.154	Guideline on Active Substance Master File Procedure (June 2012)	1–30
2.155	Additional Guidance on Documents Relating to an Active Substance Master File (September 2012)	1–9
2.156	Clinical development of Medicinal Products Intended for the Treatment of Chronic Primary Immune Thrombocytopenia (February 2014)	1–17
2.157	Evaluation of Medicinal Products for the Treatment of Irritable Bowel Syndrome (September 2014).....	1–19
2.158	Clinical Investigation of Medicinal Products for the Treatment of Systemic Lupus Erythematosus and Lupus Nephritis (February 2015)	1–16

EU – Tierversuche		
2.160	Richtlinie 2010/63/EU des Europäischen Parlaments und des Rates zum Schutz der für wissenschaftliche Zwecke verwendeten Tiere (September 2010)	1–70
ICH – Leitlinien für Humanarzneimittel (hum)		
2.200	International Conference on Harmonisation (ICH) – Einführung	1–2
2.201	Steps in the ICH Process for Harmonisation of Guidelines	1–2
2.202	Stability Testing of New Drug Substances and Products (Revision 2 – February 2003)	1–21
2.202a	Quality of Biotechnological Products: Stability Testing of Biotechnological/Biological Products (December 1995)	1–9
2.202b	Stability Testing: Requirements for New Dosage Forms (1996)	1
2.202c	Bracketing and Matrixing Design for Stability Testing of New Drug Substances and Products (February 2002)	1–8
2.202d	Evaluation of Stability Data (February 2003)	1–17
2.202e	Stability Data Package for Registration Applications in Climatic Zones III and IV (June 2006)	1–2
2.203	Detection of Toxicity to Reproduction for Medicinal Products (1993)	1–18
2.203a	Toxicity to Male Fertility (December 1995)	1–3
2.204	Studies in Support of Special Populations: Geriatrics (1993)	1–5
2.205	Validation of Analytical Methods: Definitions and Terminology (November 1994)	1–5
2.205a	Validation of Analytical Procedures: Methodology (December 1996)	1–8
2.205b	Guideline on Bioanalytical Method Validation (nicht ICH) (July 2011)	1–23
2.206	Pharmacokinetics: Guidance for Repeated Dose Tissue Distribution Studies (1994)	1–2
2.207	The Extent of Population Exposure to Assess Clinical Safety for Drugs Intended for Long-Term Treatment of Non-Life Threatening Conditions (November 1994)	1–3
2.208	Dose-Response Information to Support Drug Registration (1994) ...	1–11
2.208a	Duration of Chronic Toxicity Testing in Animals (Rodent and Non Rodent Toxicity Testing) (November 1998)	1–2
2.209	Toxicokinetics: The Assessment of Systemic Exposure in Toxicity Studies (1994)	1–11
2.209a	ICH S74 – Note for Guidance on Safety Pharmacology Studies for Human Pharmaceuticals (November 2000)	1–9
2.210	Dose Selection for Carcinogenicity Studies of Pharmaceuticals (April 2008)	1–9
2.210a	Guideline on the Need for Carcinogenicity Studies of Pharmaceuticals – ICH Harmonised Tripartite Guideline [EMA Status as of December 1995]	1–4

2.210b	Testing for Carcinogenicity of Pharmaceuticals – ICH Harmonised Tripartite Guideline (September 1997)	1–7
2.210c	Guideline on Potency Testing of Cell Based Immunotherapy Medicinal Products for the Treatment of Cancer (nicht ICH) (November 2007)	1–7
2.211d	Clinical Safety Data Management: Definitions and Standards for Expedited Reporting – ICH Harmonised Tripartite Guideline – ICH E2D (November 2003)	1–13
2.213	Guideline for Good Clinical Practice – ICH Harmonised Tripartite Guideline – EMEA Status as of June 1996 (June 1996)	1–50
2.213a	Explanatory Note and Comments to the ICH Harmonised Tripartite Guideline E6: Note for Guidance on Good Clinical Practice (September 1997)	1–6
2.214	Structure and Content of Clinical Study Reports – ICH Harmonised Tripartite Guideline [EMA Status as of December 1995] (July 1996)	1–45
2.215	General Considerations for Clinical Trials – ICH Harmonised Tripartite Guideline (September 1997)	1–13
2.216	Statistical Principles for Clinical Trials – ICH Harmonised Tripartite Guideline (March 1998)	1–41
2.217	Ethnic Factors in the Acceptability of Foreign Clinical Data – ICH Harmonised Tripartite Guideline (March 1998)	1–15
2.218	Choice of Control Group in Clinical Trials – ICH Topic E 10 (July 2000)	1–32
2.219	Clinical Investigation of Medicinal Products in the Paediatric Population – ICH Topic E 11 (July 2000)	1–13
2.220	Guideline on the Development of New Medicinal Products for the Treatment of Ulcerative Colitis (nicht ICH) (January 2008)	1–12
2.220a	Note for Guidance on Non-clinical Evaluation for Anticancer Pharmaceuticals – ICH Topic S9 (November 2009)	1–9
2.221	Pharmaceutical Development – ICH Q8 (November 2005)	1–8
2.221a	Pharmaceutical Development – ICH Topic Q8 Annex (December 2008)	1–16
2.222	Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances (November 1999)	1–33
2.223	Impurities Testing Guideline: Impurities in New Drug Substances – ICH Topic Q3A (R2) (October 2006)	1–13
2.224	Impurities in New Drug Products – ICH Topic Q3B (R2) Revision (June 2006)	1–13
2.224a	Guideline on Elemental Impurities (ICH Q3D) (January 2015)	1–73
2.224b	Elemental Impurities in Marketed Products. Recommendations for Implementation (February 2015)	1–2
2.225	Impurities: Guideline for Residual Solvents – ICH Topic Q3C (R5) (March 2011)	1–23

2.225a	Annexes to: CPMP/ICH/283/95 Impurities: Guideline for Residual Solvents & CVMP/VICH/502/99 Guideline on Impurities: Residual Solvents (February 2013).....	1–5
2.227	Photostability Testing of New Active Substances and Medicinal Products [ICH Harmonised Tripartite Guideline] (December 1996).....	1–9
2.228	Clinical Evaluation of QT/QTc Interval Prolongation and Pro-arrhythmic Potential for Non-Antiarrhythmic Drugs – ICH Topic E14 (May 2005)	1–16
2.229	Non-Clinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals – ICH S7B (May 2005).....	1–10
2.230	Guideline on Genotoxicity Testing and Data Interpretation for Pharmaceuticals Intended for Human Use – ICH Guideline S2 (R1) (November 2011)	1–27
2.230a	Limits of Genotoxic Impurities (nicht ICH) (June 2006)	1–9
2.231a	Guideline on the Assessment of Genotoxicity of Herbal Substances/Preparations (nicht ICH) (May 2008)	1–12
2.231b	Photosafety Evaluation of Pharmaceuticals – ICH Topic S10 (January 2014)	1–16
2.232	Non-Clinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals – ICH Topic M 3 (R2) (June 2009).....	1–27
2.232a	Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk (ICH M7) (September 2014).....	1–29
2.233	Pre-Clinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals (ICH Guideline S6 (R1) (July 2011).....	1–23
2.234	Quality of Biotechnological Products: Derivation and Characterisation of Cell Substrates Used for Production of Biotechnological/Biological Products – ICH Harmonised Tripartite Guideline (September 1997).....	1–13
2.235	Quality of Biotechnological Products: Analysis of the Expression Construct in Cells Used for Production of r-DNA Derived Protein Products – ICH Harmonised Tripartite Guideline [EMA Status as of December 1995] (December 1995)	1–5
2.236	Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin [ICH Harmonised Tripartite Guideline] (April 1997)	1–30
2.237	Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products (ICH Harmonised Tripartite Guideline) (March 1999)	1–18
2.238	Comparability of Biotechnological/Biological Products Subject to Changes in their Manufacturing Process (ICH Q5E) (December 2004)	1–13
2.239	Immunotoxicity Studies for Human Pharmaceuticals (ICH Topic S 8) (October 2005)	1–12

2.241	Q11 on Development and Manufacture of Drug Substances (Chemical Entities and Biotechnological/Biological Entities) (ICH Q11) (May 2012).....	1–30
2.242	ICH Q7 A – Good Manufacturing Practice for Active Pharmaceutical Ingredients (November 2000)	1–45
2.243	Pharmaceutical Quality System (ICH Q10) (January 2011).....	1–18
2.244	Quality Risk Management (ICH Q9) (January 2011)	1–20
	EU – Umweltverträglichkeitsprüfung (ERA) und Risiken durch genetisch veränderte Organismen (GMOs) (hum)	
2.245	Guideline on Environmental Risk Assessments for Medicinal Products Consisting of or Containing Genetically Modified Organisms (GMOs) (December 2006)	1–15
2.250	Richtlinie des Rates über die Anwendung genetisch veränderter Mikroorganismen in geschlossenen Systemen (90/219/EWG) (April 1990)	1–19
2.251	Richtlinie des Rates über die absichtliche Freisetzung genetisch veränderter Organismen in der Umwelt (90/220/EWG) (April 1990)	1–20
2.252	Richtlinie des Rates über den Schutz der Arbeitnehmer gegen Gefährdung durch biologische Arbeitsstoffe bei der Arbeit (November 1990)	1–20
2.255	Environmental Risk Assessment of Medicinal Products for Human Use (June 2006)	1–13
2.256	Guideline on Scientific Requirements for the Environmental Risk Assessment of Gene Therapy Medicinal Products (May 2008)	1–16
	EU – Summary of Product Characteristics (SmPC) und Core SPC (hum)	
2.350	Guideline on Summary of Product Characteristics (SmPC) (September 2009).....	1–33
2.350a	Core SmPC for Radiopharmaceuticals (July 2010)	1–11
2.351	Guideline for the SPC of Angiotensin Converting Enzyme Inhibitors (1994).....	1–8
2.352	Summary of Product Characteristics (Part 1B) for Benzodiazepines as Anxiolytics or Hypnotics (1994)	1–5
2.353	Guideline on Core SmPC for Human Normal Immunoglobulin for Intravenous Administration (IVIg) (December 2012)	1–12
2.353a	Core SPC for Human Normal Immunoglobulin for Subcutaneous and Intramuscular Administration (February 2015)	1–11
2.353b	Core SPC for Human Varicella Immunoglobulin for Intramuscular Use (July 2005).....	1–6
2.353c	Core SPC for Human Rabies Immunoglobulin for Intramuscular Use (July 2005)	1–6
2.353d	Core SPC for Human Tetanus Immunoglobulin for Intramuscular Use (July 2005).....	1–6

2.353e	Core SPC for Human Tick-Borne Encephalitis Immunoglobulin for Intramuscular Use (July 2005)	1–6
2.353f	Core SPC for Human Plasma Derived Hepatitis B Immunoglobulin for Intramuscular Use (April 2006)	1–6
2.353g	Core SPC for Human Plasma Derived Hepatitis B Immunoglobulin for Intravenous Use (April 2006)	1–7
2.354	Core SPC for Human Albumin Solution (November 2005)	1–8
2.354a	Core SPC for Human Plasma Derived Coagulation Factor VII Products (July 2004)	1–6
2.355	Guideline on Core SmPC for Human Plasma-Derived and Recombinant Coagulation Factor VIII Products (May 2012)	1–9
2.356	Core SmPC for Human Plasma Derived and Recombinant Coagulation Factor IX Products (December 2014)	1–10
2.356a	Core SPC for Human Plasma Derived Antithrombin (January 2002)	1–6
2.356b	Core SPC for Human Plasma Derived von Willebrand Factor (November 2005)	1–7
2.357	Guideline on the Core SPC for Human Anti-D Immunoglobulin for Intramuscular Use – Revision 1 (September 2007)	1–9
2.357a	Core SPC for Human Anti-D Immunoglobulin for Intravenous Use Revision 1 (September 2007)	1–9
2.358	Core SPC for Plasma Derived Fibrin Sealant/Haemostatic Products (July 2004)	1–6
2.358a	Guideline on Core SmPC for Human Fibrinogen Products (January 2009)	1–6
2.359	Core SPC for Human Prothrombin Complex Products (October 2004)	1–7
2.359a	Core SPC for Pandemic Influenza Vaccines (July 2009)	1–6
2.360	Description of Composition of Pegylated (Conjugated) Proteins in the SPC (July 2003)	1–2
2.362	Guideline on Declaration of Herbal Substances and Herbal Preparations in Herbal Medicinal Products/Traditional Herbal Medicinal Products in the SPC (July 2007)	1–14
2.365	Pharmaceutical Aspects of the Product Information for Human Vaccines (December 2003)	1–13
2.370	I Iodomethyl Norcholesterol (Injection) (December 1994)	1–6
2.371	Technetium (^{99m} Tc) Generator (December 1994)	1–9
2.372	Kit for the Preparation of (^{99m} Tc) Technetium – 1,1,3,3 – Propanetetrphosphonate (May 1995)	1–7
2.373	Kit for the Preparation of (^{99m} Tc) Technetium – Phytate (May 1995)	1–7
2.374	Iodinated (¹²⁵ I) Human Fibrinogen (Injection) (May 1995)	1–5
2.375	Sodium Iodide ¹³¹ I (Injection) (May 1995)	1–10
2.376	Sodium Iodohippurate ¹²³ I (Injection) (May 1995)	1–8
2.377	Sodium Iodohippurate ¹³¹ I (Injection) (May 1995)	1–8
2.378	¹³³ Xe-Xenon Gas (May 1995)	1–8
2.379	¹³³ Xe-Xenon Solution (May 1995)	1–6

2.380	Kit for the Preparation of Stannous Medronate Used for the Labeling of Red Blood Cells with 99m Technetium (Sn-MPD) (May 1995).....	1–7
2.381	Guideline on Core SmPC and Package Leaflet for Fludeoxyglucose (¹⁸ F) (July 2012).....	1–19
2.382	Core SmPC and Package Leaflet for Technetium (^{99m} Tc) Sestamibi (November 2013).....	1–22
2.383	Core SmPC and Package Leaflet for (99Mo/99mTc) Generator (December 2014)	1–24
	EU – Packmittel und Herstellungsaspekte	
2.400	Plastic Immediate Packaging Materials (May 2005)	1–11
2.410	Maximum Shelf-Life for Sterile Products for Human Use after First Opening or Following Reconstitution (January 1998).....	1–2
2.415	In-Use Stability Testing of Human Medicinal Products (February 2001)	1–3
2.420	Commission Directive 2002/72/EC Relating to Plastic Materials and Articles Intended to Come into Contact with Foodstuffs (August 2002)	1–49
2.430	Limitations to the Use of Ethylene Oxide in the Manufacture of Medicinal Products (March 2001)	1–2
2.435	Replacement of Chlorofluorocarbons (CFC) in Metered Dose Inhalation Products (December 1993)	1–9
2.436	PMS Studies for Metered Dose Inhalers with New Propellants (1995).....	1–3
2.437	Pharmaceutical Quality of Inhalation and Nasal Products (March 2006)	1–28
2.438	Requirements for Clinical Documentation for Orally Inhaled Products (January 2009).....	1–29
2.440	Matters Relating to the Replacement of CFCs in Medicinal Products (December 1993)	1–4
2.445	Commission Decision (2000/22/EC) of 16 December 1999 on the Allocation of Quantities of Controlled Substances Allowed for Essential Uses in the Community in 2000 under Council Regulation (EC) no 3093/94 on Substances that Deplete the Ozone Layer (2000/22/EC).....	1–7
2.450	Guideline on Excipients in the Dossier for Application for Marketing Authorisation of a Medicinal Product (July 2007)	1–12
2.455	Inclusion of Antioxidants and Antimicrobial Preservatives in Medicinal Products (July 1997)	1–5
2.460	The Use of Phthalates as Excipients in Human Medicinal Products (November 2014)	1–12
2.461	The Use of Porcine Trypsin Used in the Manufacture of Human Biological Medicinal Products (February 2014).....	1–8
2.525	Guidelines on Conduct of Pharmacovigilance for Medicines used by the Paediatric Population (January 2007)	1–14

2.540	Exposure to Medicinal Products During Pregnancy: Need for Post-Authorisation Data (November 2005)	1–24
2.541	Guideline on Risk Assessment of Medicinal Products on Human Reproduction and Lactation: From Data to Labelling (July 2008)	1–20
2.600	Commission Directive 2003/94/EC Laying Down the Principles and Guidelines of Good Manufacturing Practice in Respect of Medicinal Products for Human Use and Investigational Medicinal Products for Human Use (October 2003)	1–8
	EU – Leitlinien für Tierarzneimittel (vet)	
2.700	EU-Leitlinien für die Prüfung von Tierarzneimitteln – Einführung ..	1–2
2.702	Guidelines on Statistical Principles for Veterinary Clinical Trials for Veterinary Medicinal Products (Pharmaceuticals) (January 2012)	1–35
2.704	Anticoccidials Used for the Therapy of Coccidiosis in Chickens, Turkeys and Geese (May 1993)	1–8
2.705	Performance Enhancers (May 1991)	1–4
2.706	Veterinary Medicinal Products for Fluid Therapy in Case of Diarrhoea (September 1992)	1–4
2.707	Guideline on Veterinary Medicinal Products Controlling Varroa Destructor Parasitosis in Bees (November 2010)	1–9
2.708	Demonstration of Efficacy of Ectoparasiticides (September 1994)...	1–7
2.708a	Specific Efficacy Requirements for Ectoparasiticides in Sheep (July 2002)	1–7
2.709	Local Tolerance of Intramammary Preparations in Cows (November 1992)	1–3
2.710	Evaluation of the Safety of Veterinary Medicinal Products for the Target Animals (September 1994)	1–7
2.711	Guideline on Dossier Requirements for Anticancer Medicinal Products for Dogs and Cats (April 2009)	1–28
2.715	Validation of Analytical Procedures: Methodology (December 1998)	1–9
2.716	Validation of Analytical Procedures: Definition and Terminology (December 1998)	1–5
2.720	Conduct of Pharmacokinetic Studies in Animals (March 1992)	1–5
2.725	Conduct of Bioequivalence Studies for Veterinary Medicinal Products (April 2011)	1–27
2.726	Demonstration of Palatability of Veterinary Medicinal Products (November 2014)	1–7
2.727	Data Requirements for Changes to the Strain Composition of Authorised Equine Influenza Vaccines in Line with OIE Recommendations (November 2014)	1–8
2.730	Guideline on Pharmaceutical Fixed Combination Products (December 2006)	1–7
2.738	Guideline on Data Requirements to Support In-Use Stability Claims for Veterinary Vaccines (March 2010)	1–4

2.739	Maximum Shelf-Life for Sterile Veterinary Products After First Opening or Following Reconstitution (July 2000)	1
2.740	In-Use Stability Testing of Veterinary Medicinal Products (February 2002)	1–4
2.740a	Declaration of Storage Conditions in the Product Information of Pharmaceutical Veterinary Medicinal Products (July 2003)	1–4
2.740b	Declaration of Storage Conditions for Active Substances (July 2003)	1
2.741	Excipients in the Dossier for Application for Marketing Authorisation in Veterinary Medicinal Products (February 1999)	1–6
2.742	Investigation of Chiral Active Substances (June 1997)	1–10
2.745	Additional Quality Requirements for Products Intended for Incorporation into Animal Feedings (Medicated Premixes) (December 1996)	1–4
EU – Pharmacovigilanz (vet)		
2.747a	Guideline on EU Veterinary Suspected Adverse Reaction Report Form for Veterinarians and Health Professionals (June 2005)	1–3
2.756	Conduct of Post-Marketing Surveillance Studies of Veterinary Medicinal Products (April 2000)	1–6
2.759	Pre-Authorisation Studies to Assess the Potential for Resistance Resulting from the Use of Antimicrobial Veterinary Medicinal Products (July 2002)	1–7
EU – Umweltverträglichkeitsprüfung (ERA) (vet)		
2.760	Determining the Fate of Veterinary Medicinal Products in Manure (March 2011)	1–10
2.761	Guidance on Environmental Risk Assessment for Veterinary Medicinal Products Consisting of or Containing Genetically Modified Organisms (GMOs) as or in Products (March 2006)	1–21
2.764	Environmental Impact Assessment for Veterinary Medicinal Products Phase II (VICH-GL 38) (November 2004)	1–34
2.765	Environment Risk Assessment for Immunological Veterinary Medicinal Products (July 1996)	1–7
2.766	Guideline on Environmental Impact Assessment For Veterinary Medicinal Products – In Support of the VICH Guidelines GL6 and GL38 (April 2007)	1–72
2.767	Guidance on the Assessment of Environmental Risks of Veterinary Medicinal Products (June 2009)	1–5
EU – Tierarzneimittelrückstände (MRL) (vet)		
2.768	Regulation (EC) No 470/2009 of the European Parliament and of the Council laying down Community Procedures for the Establishment of Residue Limits of Pharmacologically Active Substances in Foodstuffs of Animal Origin, repealing Council Regulation (EEC) No 2377/90 and amending Directive 2001/82/EC of the European Parliament and of the Council and Regulation (EC) No 726/2004 of the European Parliament and of the Council (May 2009)	1–19

2.769	Commission Regulation (EU) No 37/2010 on Pharmacologically Active Substances and their Classification Regarding Maximum Residue Limits in Foodstuffs of Animal Origin (January 2010)	1–97
2.769a	Substances Considered as not Falling within the Scope of Regulation (EC) No. 470/2009, with Regard to Residues of Veterinary Medicinal Products in Foodstuffs of Animal Origin (June 2015).....	1–5
2.770	Guideline on Data to be Provided in Support a Request to Include a Substance in the List of Substances Considered as Not Falling Within the Scope of Regulation (EC) No 470/2009 (November 2010)...	1–8
2.770a	Risk Analysis Approach for Residues of Veterinary Medicinal Products in Food of Animal Origin (January 2001).....	1–12
2.771	Establishment of Maximum Residue Limits for Minor Animal Species (November 1997).....	1–5
2.772	Establishment of Maximum Residue Limits for <i>Salmonidae</i> and Other Fin Fish (January 1998)	1
2.773	Status of MRL Procedures – MRL Assessments in the Context of Council Regulation (EEC) No 2377/90 (July 2009)	1–26
2.774	Risk Characterisation and Assessment of Maximum Residue Limits (MRL) for Biocides (January 2015)	1–20
EU – Developement Pharmaceutics (vet)		
2.778	Development Pharmaceutics (Veterinary) (August 1999)	1–9
2.779	Decision Trees for the Selection of Sterilisation Methods – Annex to Note for Guidance on Developement Pharmaceutics (February 2000)	1–3
2.780	Manufacture of the Finished Dosage Form (December 1995)	1–6
2.780a	Quality of Modified Release Dosage Forms for Veterinary Use (July 2003)	1–11
2.783	Conduct of Pharmacokinetic Studies in Target Animal Species (March 2000)	1–6
2.785	Specific Requirements for the Production and Control of Allergen Products (1994)	1–9
2.791	DNA Vaccines Non-Amplifiable in Eukaryotic Cells for Veterinary Use (March 2000)	1–6
2.791a	Live Recombinant Vector Vaccines for Veterinary Use (December 2004)	1–5
2.792	Harmonisation of Requirements for Equine Influenza Vaccines Specific Requirements for Substitution or Addition of a Strain or Strains (November 1998)	1–6
2.793	Note for Guidance on the Use of Adjuvanted Veterinary Vaccines (November 1998)	1–4
2.793a	Duration of Protection Achieved by Veterinary Vaccines (October 2000)	1–4
2.793b	Field Trials with Veterinary Vaccines (June 2001)	1–6
2.794	Requirements for Combined Vaccines and Associations of Immunological Veterinary Medicinal Products (IVMPs) (July 2013)	1–12

2.794a	Design of Studies to Evaluate the Safety and Efficacy of Fish Vaccines (November 2011)	1–10
2.794k	Guideline on Requirements for an Authorisation under Exceptional Circumstances for Vaccines for Emergency Use against Bluetongue (November 2008)	1–7
2.795	Inclusion of Antimicrobial Preservatives in Immunological Veterinary Medicinal Products (July 1997)	1–3
2.795a	Requirements and Controls Applied to Bovine Serum Used in the Production of Immunological Veterinary Medicinal Products (November 2005)	1–7
2.796	Veterinary Medicinal Products for Zootechnical Purposes (March 1992)	1–3
2.797	Testing and Evaluation of the Efficacy of Antiparasitic Substances for the Treatment and Prevention of Tick and Flea Infestation in Dogs and Cats (November 2007)	1–17
2.800	Guideline on Requirements for the Production and Control of Immunological Veterinary Medicinal Products (June 2012)	1–10
2.802	Note for Guidance for the Assessment of the Effect of Antimicrobial Substances on Dairy Starter Cultures (March 2000)	1–7
2.805	Conduct of Efficacy Studies for -Non-Steroidal Anti-Inflammatory Drugs (January 2014)	1–10
2.806	Efficacy of Veterinary Medicinal Products for Use in Farmed Aquatic Species (September 1994)	1–14
2.810	Guidelines for the Conduct of Efficacy Studies for Intramammary Products for use in Cattle (Revision 1 – February 2003)	1–6
2.815	Demonstration of Efficacy for Veterinary Medicinal Products containing Antimicrobial Substances (December 2002)	1–7
2.832	EMA Report on the Implementation of the Possibility for Waiving the Target Animal Batch Safety Test for Immunological Veterinary Medicinal Products in the European Union (January 2012)	1–4
2.833	Guideline on Data Requirements for Removing the Target Animal Batch Safety Test for Immunological Veterinary Medicinal Products in the EU (January 2012)	1–4
2.834	Biologicals: Harmonization of Criteria to Waive Target Animal Batch Safety Testing for Inactivated Vaccines for Veterinary Use – VICH GL50 (March 2013)	1–7
2.835	User Safety for Pharmaceutical Veterinary Medicinal Products (March 2010)	1–20
	EU – Summary of Product Characteristics (SmPC) (vet)	
2.840	Summary of Product Characteristics for Pharmaceutical Veterinary Medicinal Products (July 2006)	1–20
2.842	Revised Guideline on the SPC for Antimicrobial Products (November 2007)	1–6
2.843	Guideline on the Summary of Product Characteristics for Anthelmintics (July 2007)	1–5

VICH – Leitlinien für Tierarzneimittel – Wirksamkeit	
2.845	International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products (VICH) – Einführung 1
2.845a	VICH Process – The 9-steps of VICH process – The official Organisational Charter 1–3
2.846	Efficacy of Anthelmintics: Specific Recommendations for Equines (VICH Topic GL 15) (July 2001)..... 1–5
2.847	Efficacy of Anthelmintics: Specific Recommendations for Porcines (VICH Topic GL 16) (July 2001)..... 1–5
2.848	Efficacy of Anthelmintics: Specific Recommendations for Canines (VICH Topic GL 19) (July 2001)..... 1–5
2.849	Efficacy of Anthelmintics: Specific Recommendations for Felines (VICH Topic GL 20) (July 2001)..... 1–5
2.850	Efficacy of Anthelmintics: Specific Recommendations for Poultry – Gallus Gallus (VICH Topic GL 21) (July 2001)..... 1–4
2.851	Efficacy of Anthelmintics: General Requirements (EAGR) (VICH GL7) (December 1999)..... 1–9
2.852	Efficacy of Anthelmintics: Specific Recommendations for Bovines (VICH GL12) (December 1999)..... 1–5
2.853	Efficacy of Anthelmintics: Specific Recommendations for Ovines (VICH GL13) (December 1999)..... 1–5
2.854	Efficacy of Anthelmintics: Specific Recommendations for Caprines (VICH GL14) (December 1999)..... 1–5
EU/VICH – Qualität (vet)	
3.855	Stability Testing for Medicated Premixes (December 1999)..... 1–2
2.856	Guideline on the Quality Aspects of Single-Dose Veterinary Spot-on Products (January 2009)..... 1–4
2.857	Impurities in New Veterinary Drug Substances (VICH GL10) (February 2007) 1–13
2.858	Impurities in New Veterinary Medicinal Products (VICH GL11) (February 2007) 1–11
2.858a	Guideline on Setting Specifications for Related Impurities in Antibiotics (June 2012)..... 1–18
2.859	Impurities: Residual Solvents in New Veterinary Medicinal Products, Active Substances and Excipients – VICH GL18(R) (September 2011) 1–16
2.859a	Testing of Residual Formaldehyde (VICH GL25) (April 2002)..... 1–5
2.859b	Testing of Residual Moisture (VICH GL26) (April 2002) 1–3
2.859c	Biologicals: Testing for the Detection of Mycoplasma Contamination – VICH GL34 (March 2013) 1–15
2.860	Stability Testing of Biotechnological/Biological Veterinary Medicinal Products (VICH GL17)(June 2000) 1–10
2.861	Stability Testing of New Veterinary Drug Substances and Medicinal Products (VICH GL3) (February 2007)..... 1–21

2.861a	Quality: Statistical Evaluation of Stability Data – VICH GL51 (March 2013)	1–18
2.862	Stability Testing for New Veterinary Dosage Forms (VICH GL4) (June 1999).....	1
2.863	Stability Testing: Photostability Testing of New Veterinary Drug Substances and Medicinal Products (VICH GL5) (June 1999)	1–9
2.864	Quality Aspects of Pharmaceutical Veterinary Medicines for Administration via Drinking Water (July 2004)	1–8
2.865	Chemistry of New Active Substances (May 2004).....	1–12
2.866	Stability Testing of Existing Active Substances and Related Finished Products (August 2008).....	1–18
2.867	Quality: Bracketing and Matrixing Designs for Stability Testing of New Veterinary Drug Substances and Medicinal Products (VICH GL45) (April 2010).....	1–8
2.868	Parametric Release (October 2006)	1–7
EU/VICH – Tierarzneimittelrückstände (vet)		
2.870	Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: General Approach to Establish a Microbiological ADI (VICH GL36(R)) (July 2012)	1–27
2.870a	Approach to Establish a Pharmacological ADI (November 2012)	1–6
2.871	Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: Repeat-Dose (Chronic) Toxicity Testing (VICH GL 37) (June 2004).....	1–4
2.872	Pre-Approval Information for Registration of New Veterinary Medicinal Products for Food-producing Animals with Respect to Antimicrobial Resistance (VICH Topic GL 27) (January 2004)	1–7
2.873	Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: General Approach to Testing (VICH Topic GL 33) (April 2009)	1–5
2.873a	Studies to Evaluate the Metabolism and Residue Kinetics of Veterinary Drugs in Food-Producing Animals: Metabolism Study to Determine the Quantity and Identify the Nature of Residues (VICH GL 46) (February 2011)	1–11
2.873b	Studies to Evaluate the Metabolism and Residue Kinetics of Veterinary Drugs in Food-Producing Animals: Laboratory Animal Comparative Metabolism Studies (VICH GL47) (March 2011)	1–9
2.873c	Studies to Evaluate the Metabolism and Residue Kinetics of Veterinary Drugs in Food-Producing Animals: Marker Residue Depletion Studies to Establish Product Withdrawal Periods (VICH GL48) (February 2015)	1–14
2.873d	Studies to Evaluate the Metabolism and Residue Kinetics of Veterinary Drugs in Human Food-Producing Animals: Validation of Analytical Methods Used in Residue Depletion Studies (VICH GL 49) (February 2015)	1–16

2.874	Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: Reproduction Testing (VICH TOP GL 22) (July 2001)	1–5
2.875	Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: Genotoxicity Testing (VICH GL23) (November 2014)	1–6
2.876	Safety of Residues: Repeat-Dose (90-Day) Toxicity Testing (VICH Topic GL31) (November 2002)	1–3
2.877	Safety of Residues: Development Toxicity Testing (VICH Topic GL32) (November 2002)	1–4
2.878	Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: Carcinogenicity Testing (VICH GL28) (Revision May 2005)	1–4
2.879	Guideline on Injection Site Residues (October 2004)	1–12
2.880	Good Clinical Practice (VICH GL9) (June 2000)	1–21
2.881	Specifications: Test Procedures and Acceptance Criteria for New Veterinary Drug Substances and New Medicinal Products: Chemical Substances (VICH GL 39) (November 2005)	1–34
2.882	Specifications: Test Procedures and Acceptance Criteria for New Biotechnological/Biological Veterinary Medicinal Products (VICH GL 40) (November 2005)	1–19
2.883	Target Animal Safety: Examination of Live Veterinary Vaccines in Target Animals for Absence of Reversion to Virulence (VICH Topic GL 41) (July 2007)	1–6
2.884	Target Animal Safety for Veterinary Pharmaceutical Products (VICH GL 43) (July 2008)	1–16
2.885	Target Animal Safety for Veterinary Live and Inactivated Vaccines (VICH GL 44) (July 2008)	1–9
2.886	Demonstration of Target Animal Safety and Efficacy of Veterinary Medicinal Products Intended for Use in Farmed Finfish (May 2011)	1–15
2.890	Environmental Impact Assessment (EIAs) for Veterinary Medicinal Products (VMPs) – Phase I (VICH GL6) (June 2000)	1–7
2.910	Guideline on Requirements for an Authorisation under Exceptional Circumstances for Vaccines for Use in Birds against Avian Influenza (April 2007)	1–9
2.915	Guideline on Data Requirements for Multi-Strain Dossiers for Inactivated Vaccines Against Avian Influenza (AI), Bluetongue (BT) and Foot-And-Mouth Disease (FMD) (March 2010)	1–7
2.935	Guideline for an Assessor Preparing Assessment Reports for Veterinary Medicinal Products (May 2005)	1–51
2.953	Guideline on Monitoring of Compliance with Pharmacovigilance Regulatory Obligations and Pharmacovigilance Inspections for Veterinary Medicinal Products (March 2007)	1–17
2.960	Management of Periodic Summary Update Reports (PSUs) (June 2006)	1–3

EU – Minor Uses or Minor Species (MUMS) (vet)	
2.975	Quality Data Requirements for Veterinary Medicinal Products Intended for Minor Uses or Minor Species (July 2006) 1–9
2.977	Guideline on Efficacy and Target Animal Safety Data Requirements for Veterinary Medicinal Products Intended for Minor Uses or Minor Species (July 2006) 1–7
2.980	Safety and Residues Data Requirements for Veterinary Medicinal Products Intended for Minor Uses or Minor Species (July 2006) 1–27
EU – Orphan Medicinal Products (OMP)	
2.1000	Regulation (EC) No 141/2000 of the European Parliament and of the Council on Orphan Medicinal Products (December 1999)..... 1–8
2.1001	Commission Regulation (EC) No 847/2000 Laying down the Provisions for Implementation of the Criteria for Designation of a Medicinal Product as an Orphan Medicinal Product and Definitions of the Concepts ‘Similar Medicinal Product’ and ‘Clinical Superiority’ (April 2000) 1–6
EU – Implementierung von GCP (hum)	
2.1010	Clinical Trials in Small Populations (July 2006) 1–12
2.1100	Directive 2001/20/EC of the European Parliament and of the Council on the Approximation of the Laws, Regulations and Administrative Provisions of the Member States Relating to the Implementation of Good Clinical Practice in the Conduct of Clinical Trials on Medicinal Products for Human Use (April 2001)..... 1–18
2.1101	Regulation (EC) No 1901/2006 of the European Parliament and of the Council on Medicinal Products for Paediatric Use and Amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004 (December 2006) ... 1–31
2.1102	Regulation (EC) No 1902/2006 of the European Parliament and of the Council amending Regulation 1901/2006 on Medicinal Products for Paediatric Use (December 2006) 1–2
2.1103	Leitlinie der Kommission für Format und Inhalt von Anträgen auf Billigung oder Änderung eines pädiatrischen Prüfkonzepts sowie auf Freistellung oder Zurückstellung und für die Prüfung auf Übereinstimmung und die Kriterien zur Bewertung wesentlicher Studien (September 2008) 1–23
2.1105	Investigational Medicinal Products (IMPs) and „Non Investigational Medicinal Products“ (NIMPS) (Rev.1, March 2011)..... 1–12
2.1110	Requirements to the Chemical and Pharmaceutical Quality Documentation Concerning Investigational Medicinal Products in Clinical Trials (October 2006) 1–31
2.1113	Guideline on Virus Safety Evaluation of Biotechnological Investigational Medicinal Products (July 2008) 1–10
2.1300	Definitions for Genomic Biomarkers, Pharmacogenomics, Pharmacogenetics, Genomic Data and Sample Coding Categories (ICH Topic E 15) (November 2007) 1–6

2.1310	Genomic Biomarkers Related to Drug Response: Context, Structure and Format of Qualification Submissions (ICH E16) (September 2010)	1–10
	EU – Plasma Master File (PMF) und Vaccine Antigen Master File (VAMF)	
2.1500	Guideline on the Scientific Data Requirements for a Plasma Master File (PMF) (November 2006)	1–37
2.1502	Guideline on Epidemiological Data on Blood Transmissible Infections (April 2010)	1–15
2.1503	Requirements for Plasma Master File (PMF) Certification (February 2004)	1–11
2.1505	Scientific Data Requirements for a Vaccine Antigen Master File (December 2003)	1–5
2.1510	Requirements for Vaccine Antigen Master File (VAMF) Certification (Revision 1 – March 2005)	1–12
2.1515	Guideline on Plasma Master File (PMF) and Vaccine Antigen Master File (VAMF) „Second Step“ (2004)	1–4
	EU – Zellpräparate und Arzneimittel für neuartige Therapien (hum)	
2.1605	Guideline on Human Cell-Based Medicinal Products (May 2008)	1–27
2.1610	Guideline on Xenogeneic Cell-Based Medicinal Products (October 2009)	1–15
2.1700	Non-Clinical and Clinical Development of Similar Medicinal Products Containing Recombinant Interferon Alfa (April 2009)	1–7
2.1705	Guideline on the Non-Clinical Studies Required Prior to Clinical Use of Gene Therapy Medicinal Products (May 2008)	1–11
2.1710	Guideline on Follow-Up of Patients Administered with Gene Therapy Medicinal Products (October 2009)	1–14
2.1805	Guideline on the Clinical and Non-Clinical Evaluation During the Consultation Procedure on Medicinal Substances Contained in Drug-Eluting (Medicinal Substance-Eluting) Coronary Stents (May 2008)	1–11
2.1810	Risk-Based Approach According to Annex I, Part IV of Directive 2001/83/EC Applied to Advanced Therapy Medicinal Products (February 2013)	1–25
	EU – Community Herbal Monographs	
2.1995	Community Herbal Monographs – Einführung	1
2.1996	Guideline on the Documentation to be Submitted for Inclusion into the ‘Community List of Herbal Substances, Preparations and Combinations thereof for Use in Traditional Herbal Medicinal Products’ (Revision July 2007)	1–4
2.1997	Glossary on Herbal Teas (July 2010)	1–6
2.2000	Procedure for the Preparation of Community Monographs for Herbal Medicinal Products with Well-Established Medicinal Use (January 2007)	1–10

2.2001 Community Herbal Monograph on <i>Aloe Barbadosensis</i> Miller and on <i>Aloe</i> (Various Species, Mainly <i>Aloe Ferox</i> Miller and its Hybrids) (September 2006)	1–10
2.2002 Community Herbal Monograph on <i>Cassia Senna</i> L., Fructus and <i>Cassia Angustifolia</i> Vahl, Fructus (July 2008)	1–11
2.2003 Community Herbal Monograph on <i>Linum Usitatissimum</i> L., Semen (July 2006)	1–8
2.2004 Community Herbal Monograph on <i>Plantago Afra</i> L. et <i>Plantago Indica</i> L., Semen (May 2013)	1–11
2.2005 Community Herbal Monograph on <i>Plantago Ovata</i> Forssk., Semen (May 2013)	1–10
2.2006 Community Herbal Monograph on <i>Plantago Ovata</i> Forssk., Seminis Tegumentum (May 2013)	1–11
2.2007 Community Herbal Monograph on <i>Rhamnus Frangula</i> L., Cortex (September 2006)	1–10
2.2008 Community Herbal Monograph on <i>Foeniculum Vulgare</i> Miller Subsp. <i>Vulgare</i> Var. <i>Dulce</i> (Miller) Thellung, Fructus (July 2007) ...	1–6
2.2009 Community Herbal Monograph on <i>Foeniculum Vulgare</i> Miller Subsp. <i>Vulgare</i> Var. <i>Vulgare</i> , Aetheroleum (July 2007)	1–6
2.2010 Community Herbal Monograph on <i>Foeniculum Vulgare</i> Miller Subsp. <i>Vulgare</i> Var. <i>Vulgare</i> , Fructus (July 2007)	1–6
2.2011 Community Herbal Monograph on <i>Primula Veris</i> L. and/or <i>Primula Elatior</i> (L.) Hill, Flos (September 2012)	1–5
2.2012 Community Herbal Monograph on <i>Primula Veris</i> L. and/or <i>Primula Elatior</i> (L.) Hill, Radix (September 2012)	1–7
2.2013 Community Herbal Monograph on <i>Mentha x Piperita</i> L., Aetheroleum (October 2007)	1–11
2.2014 Community Herbal Monograph on <i>Passiflora Incarnata</i> L., Herba (September 2007)	1–5
2.2015 Community Herbal Monograph on <i>Melissa Officinalis</i> L., Folium (May 2013)	1–6
2.2016 Community Herbal Monograph on <i>Rhamnus Purshianus</i> D.C., Cortex (September 2007)	1–11
2.2017 Community Herbal Monograph on <i>Rheum Palmatum</i> L. and <i>Rheum Officinale</i> Baillon, Radix (October 2007)	1–10
2.2018 Community Herbal Monograph on <i>Thymus Vulgaris</i> L. and <i>Thymus Zygis</i> L., Herba (October 2007)	1–7
2.2019 Community Herbal Monograph on <i>Pimpinella Anisum</i> L., Aetheroleum (July 2007)	1–5
2.2020 Community Herbal Monograph on <i>Pimpinella Anisum</i> L., Fructus (July 2007)	1–5
2.2021 Community Herbal Monograph on <i>Cassia Senna</i> L. and <i>Cassia Angustifolia</i> Vahl, Folium (October 2006)	1–11
2.2022 Community Herbal Monograph on <i>Valeriana Officinalis</i> L., Radix (October 2006)	1–6

2.2023	Community Herbal Monograph on <i>Equisetum Arvense</i> L., Herba (July 2008)	1-6
2.2024	Community Herbal Monograph on <i>Melilotus Officinalis</i> (L.) Lam., Herba (July 2008)	1-7
2.2025	Community Herbal Monograph on <i>Verbascum Thapsus</i> L., <i>V. Densiflorum</i> Bertol. and <i>V. Phlomoides</i> L., Flos (July 2008)	1-4
2.2026	Community Herbal Monograph on <i>Sambucus Nigra</i> L., Flos (July 2008)	1-5
2.2027	European Union Herbal Monograph on <i>Echinacea purpurea</i> (L.) Moench, herba recens (November 2014)	1-6
2.2028	Community Herbal Monograph on <i>Calendula Officinalis</i> L., Flos (May 2008)	1-6
2.2029	Community Herbal Monograph on <i>Eleutherococcus senticosus</i> (Rupr. et Maxim.) Maxim., radix (March 2014)	1-6
2.2030	Community Herbal Monograph on <i>Humulus lupulus</i> L., flos (May 2014)	1-6
2.2031	European Union Herbal Monograph on <i>Betula pendula</i> Roth and/or <i>Betula pubescens</i> Ehrh., folium (November 2014)	1-6
2.2032	Community Herbal Monograph on <i>Ruscus Aculeatus</i> L., Rhizoma (September 2008)	1-5
2.2033	Community Herbal Monograph on <i>Avena Sativa</i> L., Herba (September 2008)	1-5
2.2034	Community Herbal Monograph on <i>Avena Sativa</i> L., Fructus (September 2008)	1-4
2.2035	Community Herbal Monograph on <i>Peumus Boldus</i> Molina, Folium (January 2009)	1-5
2.2036	Community Herbal Monograph on <i>Centaurium Erythraea</i> Rafn., Herba (March 2009)	1-5
2.2037	Community Herbal Monograph on <i>Harpagophytum Procumbens</i> D.C. and/or <i>Harpagophytum Zeyheri</i> Decne, Radix (November 2008)	1-7
2.2038	Community Herbal Monograph on <i>Mentha X Piperita</i> L., Folium (September 2008)	1-5
2.2039	Community Herbal Monograph on <i>Polypodium Vulgare</i> L., Rhizoma (November 2008)	1-5
2.2040	Community Herbal Monograph on <i>Salix</i> , Cortex (January 2009)	1-7
2.2041	Community Herbal Monograph on <i>Solidago Virgaurea</i> L., Herba (September 2008)	1-5
2.2042	Community Herbal Monograph on <i>Urtica Dioica</i> L. and <i>Urtica Urens</i> L., Herba (September 2008)	1-7
2.2043	Community Herbal Monograph on <i>Artemisia Absinthium</i> L., Herba (July 2009)	1-6
2.2044	Community Herbal Monograph on <i>Althaea Officinalis</i> L., Radix (March 2009)	1-6
2.2045	Community Herbal Monograph on <i>Curcuma Longa</i> L., Rhizoma (November 2009)	1-5

2.2046 Community Herbal Monograph on <i>Echinacea Pallida</i> (Nutt.) Nutt., Radix (July 2009).....	1–5
2.2047 Community Herbal Monograph on <i>Gentiana Lutea</i> L., Radix (November 2009).....	1–5
2.2048 Community Herbal Monograph on <i>Hamamelis Virginiana</i> L., Cortex (June 2011).....	1–7
2.2049 Community Herbal Monograph on <i>Hamamelis Virginiana</i> L., Folium et Cortex aut Ramunculus Destillatum (November 2009)	1–6
2.2050 Community Herbal Monograph on <i>Hamamelis Virginiana</i> L., Folium (November 2009)	1–7
2.2051 Community Herbal Monograph on <i>Aesculus Hippocastanum</i> L., Semen (July 2009)	1–6
2.2052 Community Herbal Monograph on <i>Hypericum Perforatum</i> L., Herba (Well-Established Medicinal Use) (November 2009)	1–8
2.2053 Community Herbal Monograph on <i>Hypericum Perforatum</i> L., Herba (Traditional Use) (November 2009).....	1–9
2.2054 Community Herbal Monograph on <i>Salvia Officinalis</i> L., Folium (November 2009)	1–7
2.2055 Community Herbal Monograph on <i>Potentilla erecta</i> (L.) Raeusch., Rhizoma (November 2010).....	1–7
2.2056 Community Herbal Monograph on <i>Tanacetum parthenium</i> (L.) Schulz Bip., Herba (November 2010).....	1–4
2.2057 Community Herbal Monograph on <i>Cimicifuga racemosa</i> (L.) Nutt., Rhizoma (November 2010).....	1–6
2.2058 Community Herbal Monograph on <i>Urtica dioica</i> L.; <i>Urtica urens</i> L., Folium (January 2010)	1–6
2.2059 Community Herbal Monograph on <i>Vitis vinifera</i> L., Folium (July 2010)	1–7
2.2060 Community Herbal Monograph on <i>Orthosiphon stamineus</i> Benth., Folium (March 2010)	1–5
2.2061 Community Herbal Monograph on <i>Arctium lappa</i> L., Radix (September 2010).....	1–6
2.2062 Community Herbal Monograph on <i>Leonurus cardiaca</i> L., Herba (September 2010).....	1–6
2.2063 Community Herbal Monograph on <i>Thymus vulgaris</i> L., <i>Thymus</i> <i>zygis</i> Loeff. ex L., Aetheroleum (September 2010)	1–7
2.2064 Community Herbal Monograph on <i>Valeriana officinalis</i> L., Radix and <i>Humulus lupulus</i> L., Flos (June 2011)	1–9
2.2065 Community Herbal Monograph on <i>Ribes nigrum</i> L., Folium (May 2010).....	1–5
2.2066 Community Herbal Monograph on <i>Cola nitida</i> (Vent.) Schott et Endl. and its Varieties and <i>Cola acuminata</i> (P. Beauv.) Schott et Endl., Semen (November 2011)	1–5
2.2067 Community Herbal Monograph on <i>Chamaemelum nobile</i> (L.) All., Flos (November 2011)	1–5

2.2068	Community Herbal Monograph on <i>Agropyron repens</i> (L.) P. Beauv., Rhizoma (November 2011)	1–5
2.2069	Community Herbal Monograph on <i>Capsella bursa-pastoris</i> (L.) Medikus, Herba (July 2011).....	1–5
2.2070	Community Herbal Monograph on <i>Commiphora molmol</i> Engler, Gummi-Resina (July 2011).....	1–6
2.2071	Community Herbal Monograph on <i>Syzygium aromaticum</i> (L.) Merrill et L. M. Perry, Floris Aetheroleum (September 2011).....	1–6
2.2072	Community Herbal Monograph on <i>Cynara scolymus</i> L., Folium (July 2011)	1–6
2.2073	Community Herbal Monograph on <i>Fumaria officinalis</i> L., Herba (September 2011)	1–6
2.2074	Community Herbal Monograph on <i>Achillea millefolium</i> L., Herba (July 2011)	1–7
2.2075	Community Herbal Monograph on <i>Achillea millefolium</i> L., Flos (July 2011)	1–6
2.2076	Community Herbal Monograph on <i>Filipendula ulmaria</i> (L.) Maxim., Flos (July 2011)	1–5
2.2077	Community Herbal Monograph on <i>Filipendula ulmaria</i> (L.) Maxim., Herba (July 2011)	1–6
2.2078	Community Herbal Monograph on <i>Cinnamomum verum</i> J.S. Presl, Cortex (May 2011).....	1–6
2.2079	Community Herbal Monograph on <i>Vitex agnus-castus</i> L., Fructus (November 2011)	1–6
2.2080	Community Herbal Monograph on <i>Cinnamomum verum</i> J.S. Presl, Corticis Aetheroleum (May 2011)	1–4
2.2082	Community Herbal Monograph on <i>Taraxacum officinale</i> Weber ex Wigg., Folium (November 2009).....	1–6
2.2083	Community Herbal Monograph on <i>Taraxacum officinale</i> Weber ex Wigg., Radix cum Herba (November 2009)	1–6
2.2084	Community Herbal Monograph on <i>Hedera helix</i> L., Folium (March 2011).....	1–6
2.2085	Community Herbal Monograph on <i>Trigonella foenum-graecum</i> L., Semen (January 2011).....	1–6
2.2086	Community Herbal Monograph on <i>Echinacea purpurea</i> (L.) Moench, Radix (March 2011)	1–5
2.2087	Community Herbal Monograph on <i>Juniperus communis</i> L., Pseudo-Fructus (November 2009).....	1–7
2.2088	Community Herbal Monograph on <i>Quercus robur</i> L., <i>Quercus petraea</i> (Matt.) Liebl., <i>Quercus pubescens</i> Willd., Cortex (November 2010)	1–6
2.2089	Community Herbal Monograph on <i>Rosmarinus officinalis</i> L., Folium (July 2010).....	1–7
2.2090	Community Herbal Monograph on <i>Ilex paraguariensis</i> St. Hilaire, Folium (May 2010)	1–6

2.2091 Community Herbal Monograph on <i>Rosmarinus officinalis</i> L., Aetheroleum (July 2010)	1–6
2.2092 Community Herbal Monograph on <i>Viola tricolor</i> L. and/or sub-species <i>Viola arvensis</i> Murray (Gaud) and <i>Viola vulgaris</i> Koch (Oborny), Herba cum Flore (November 2010)	1–5
2.2093 Community Herbal Monograph on <i>Juniperus communis</i> L., Aetheroleum (November 2010)	1–6
2.2094 Community Herbal Monograph on <i>Glycyrrhiza glabra</i> L. and/or <i>Glycyrrhiza inflata</i> Bat. and/or <i>Glycyrrhiza uralensis</i> Fisch., Radix (May 2012).....	1–8
2.2095 Community Herbal Monograph on <i>Tilia cordata</i> Miller, <i>Tilia platyphyllos</i> Scop., <i>Tilia x vulgaris</i> Heyne or their mixtures, Flos (May 2012).....	1–7
2.2096 Community Herbal Monograph on <i>Fraxinus excelsior</i> L. or <i>Fraxinus angustifolia</i> Vahl, Folium (March 2012)	1–6
2.2097 Community Herbal Monograph on <i>Lavandula angustifolia</i> Miller, Aetheroleum (March 2012).....	1–5
2.2098 Community Herbal Monograph on <i>Lavandula angustifolia</i> Miller, Flos (March 2012).....	1–5
2.2099 Community Herbal Monograph on <i>Zingiber officinale</i> Roscoe, Rhizoma (March 2012)	1–6
2.2100 Community Herbal Monograph on <i>Echinacea angustifolia</i> DC., Radix (March 2012)	1–6
2.2101 Community Herbal Monograph on <i>Rhodiola rosea</i> L., Rhizoma et Radix (March 2012)	1–5
2.2102 Community Herbal Monograph on <i>Olea europaea</i> L., Folium (November 2011)	1–6
2.2103 Community Herbal Monograph on <i>Oenothera biennis</i> L.; <i>Oenothera lamarckiana</i> L., Oleum (December 2011).....	1–5
2.2104 Community Herbal Monograph on <i>Arctostaphylos uva-ursi</i> (L.) Spreng., Folium (January 2012).....	1–6
2.2105 Community Herbal Monograph on <i>Plantago lanceolata</i> L., Folium (January 2014)	1–8
2.2106 Community Herbal Monograph on <i>Livisticum officinale</i> Koch, Radix (November 2012)	1–5
2.2107 Community Herbal Monograph on <i>Solanum dulcamara</i> L., Stipites (January 2013)	1–5
2.2108 Community Herbal Monograph on <i>Pelargonium sidoides</i> DC and/ or <i>Pelargonium reniforme</i> Curt., Radix (November 2012).....	1–5
2.2109 Community Herbal Monograph on <i>Aesculus hippocastanum</i> L., Cortex (May 2012).....	1–5
2.2110 Community Herbal Monograph on <i>Urtica dioica</i> L., <i>Urtica urens</i> L., their Hybrids or their Mixtures, Radix (September 2012)	1–6
2.2111 Community Herbal Monograph on <i>Grindelia Robusta</i> Nutt., <i>Grindelia Squarrosa</i> (Pursh) Dunal, <i>Grindelia Humilis</i> Hook. et Arn., <i>Grindelia Camporum</i> Greene, Herba (November 2012)	1–5

2.2112	Community Herbal Monograph on <i>Cichorium Intybus</i> L., Radix (January 2013)	1–5
2.2113	Community Herbal Monograph on <i>Paullinia Cupana</i> Kunth ex H.B.K. var. <i>Sorbilis</i> (Mart.) Ducke, Semen (January 2013)	1–5
2.2114	Community Herbal Monograph on <i>Cucurbita Pepo</i> L., Semen (November 2012)	1–5
2.2115	Community Herbal Monograph on <i>Eucalyptus Globulus</i> Labill., Folium (April 2013)	1–6
2.2116	Community Herbal Monograph on <i>Thymus Vulgaris</i> L. and <i>Thymus Zygis</i> L., Herba and <i>Primula Veris</i> L. and <i>Primula Elatior</i> (L.) Hill, Radix (July 2013)	1–8
2.2117	Community Herbal Monograph on <i>Marrubium Vulgare</i> L., Herba (July 2013)	1–6
2.2118	Community Herbal Monograph on <i>Juglans Regia</i> L., Folium (July 2013)	1–5
2.2119	Community Herbal Monograph on <i>Phaseolus Vulgaris</i> L., Fructus sine Semine (November 2013)	1–5
2.2120	Community Herbal Monograph on <i>Origanum Dictamnus</i> L., Herba (January 2014)	1–6
2.2121	Community Herbal Monograph on <i>Rubus idaeus</i> L., Folium (January 2014)	1–6
2.2122	Community Herbal Monograph on <i>Curcuma xanthorrhiza</i> Roxb. (<i>C. xanthorrhiza</i> D. Dietrich), Rhizoma (January 2014)	1–5
2.2123	Community Herbal Monograph on <i>Panax ginseng</i> C.A.Meyer, Radix (March 2014)	1–8
2.2124	Community Herbal Monograph on <i>Eucalyptus globulus</i> Labill., <i>Eucalyptus polybractea</i> R.T. Baker and/or <i>Eucalyptus smithii</i> R.T. Baker, Aetheroleum (March 2014)	1–9
2.2125	Community Herbal Monograph on <i>Ononis spinosa</i> L., Radix (March 2014)	1–5
2.2126	European Union Herbal Monograph on <i>Hieracium pilosella</i> L., Herba cum Radice (May 2015)	1–5
2.2127	Community Herbal Monograph on <i>Arnica montana</i> L., Flos (May 2014)	1–5
2.2128	Community Herbal Monograph on <i>Fucus vesiculosus</i> L., Thallus (May 2014)	1–5
2.2129	Community Herbal Monograph on <i>Rosa gallica</i> L., <i>Rosa centifolia</i> L., <i>Rosa damascena</i> Mill., Flos (July 2014)	1–5
2.2130	European Union Herbal Monograph on <i>Sisymbrium officinale</i> (L.) Scop., Herba (September 2014)	1–6
2.2131	European Union Herbal Monograph on <i>Melaleuca alternifolia</i> (Maiden and Betch) Cheel, <i>M. linariifolia</i> Smith, <i>M. dissitiflora</i> F. Mueller and/or Other Species of <i>Melaleuca</i> , Aetheroleum (November 2014)	1–8
2.2132	European Union Herbal Monograph on <i>Cetraria islandica</i> (L.) Acharius s.l., Thallus (November 2014)	1–8

2.2133	European Union Herbal Monograph on <i>Eschscholzia californica</i> Cham., Herba (January 2015)	1–5
2.2134	European Union Herbal Monograph on <i>Capsicum annuum</i> L. var. <i>minimum</i> (Miller) Heiser and Small Fruited Varieties of <i>Capsicum frutescens</i> L., Fructus (May 2015)	1–9
2.2135	European Union Herbal Monograph on <i>Symphytum officinale</i> L., Radix (May 2015)	1–5
EU – Kinderarzneimittel		
2.5000	Pharmaceutical Development of Medicines for Paediatric Use (August 2013)	1–27
2.5001	Standard Paediatric Investigation Plan for Non-Adjuvanted or Adjuvanted Pandemic Influenza Vaccines during a Pandemic (March 2010)	1–10
2.5005	EMA/PDCO Standard Paediatric Investigation Plan for Allergen Products for Specific Immunotherapy (February 2015)	1–16
2.5006	Paediatric Investigation Plan: Expected Key Elements and Requirements for a New DTaP Containing Combination Vaccine Seeking Marketing Authorisation (September 2014)	1–4
2.5010	European Medicines Agency Decision on a Class Waiver on Condition(s) in Accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council (December 2011)	1–12
2.5015	Guideline on the Format and Content of Applications for Agreement or Modification of a Paediatric Investigation Plan and Requests for Waivers or Deferrals and Concerning the Operation of the Compliance Check and on Criteria for Assessing Significant Studies (2014/C 338/01)	1–21
2.5020	Revised Priority List for Studies on Off-Patent Paediatric Medicinal Products (August 2013)	1–14

3 Resolutionen des Europarates

3.0	Europarat – Einführung	1–2
3.1	The Quality Control of Drugs	1–4
3.2	On the Preparation and Quality Control of Radiopharmaceuticals ...	1–4
3.3	Concerning Medical Research on Human Beings – Recommendation No. R (90) 3 (February 1990)	1–4
3.10	On the Responsibilities of Health Authorities in the Field of Blood Transfusion Recommendation No. R (88) 4 (March 1988)	1–4
3.11	Europäisches Übereinkommen über den Austausch therapeutischer Substanzen menschlichen Ursprungs (Übersetzung) (Dezember 1958)	1–37
3.13	Concerning Clinical Trials Involving the Use of Components and Fractionated Products Derived from Human Blood or Plasma Recommendation No. R (93) 4 (March 1993)	1–6

3.14	On Plasma Products and European Self-Sufficiency Recommendation No. R (90) 9 (1990)	1–4
3.50	Certification of Suitability to the Monographs of the European Pharmacopoeia – Revised Version (Resolution AP-CSP (07) 1) (February 2007)	1–7
3.80	Übereinkommen zum Schutz der Menschenrechte und der Menschenwürde im Hinblick auf die Anwendung von Biologie und Medizin: Übereinkommen über Menschenrechte und Biomedizin (April 1997)	1–12
3.80a	Erläuternder Bericht zu dem Übereinkommen zum Schutz der Menschenrechte und der Menschenwürde im Hinblick auf die Anwendung von Biologie und Medizin: Übereinkommen über Menschenrechte und Biomedizin (Mai 1997).....	1–35
3.81	Zusatzprotokoll zum Übereinkommen zum Schutz der Menschenrechte und der Menschenwürde im Hinblick auf die Anwendung von Biologie und Medizin über das Verbot des Klonens von menschlichen Lebewesen (Januar 1998)	1–3
3.82	Additional Protocol to the Convention on Human Rights and Biomedicine Concerning Biomedical Research (January 2005).....	1–14
3.85	Protection of the Human Rights and Dignity of Persons with Mental Disorder (September 2004).....	1–13

4 European Directorate for the Quality of Medicines & Health Care (EDQM) – Official Control Authority Batch Release (OCABR)

4.1	Official Control Authority Batch Release (OCABR) for Human Biologicals: Vaccines, Blood and Plasma Derivatives – Background and Legal Framework – (April 2014)	1–2
4.5	OCABR Network Human Biologicals Guidelines and Procedures – Preface (December 2012)	1–2
4.10	EU Administrative Procedure for Official Control Authority Batch Release - Human Vaccine and Blood Derived Medicinal Products (March 2014)	1–30
4.15	EU Administrative Procedure for Official Control Authority Batch Release (OCABR) of Centrally Authorised Immunological Medicinal Products for Human Use and Medicinal Products Derived from Human Blood and Plasma (May 2010).....	1–2
4.20	Guidelines for EU Official Control Authority Batch Release for Human Biological Medicines – Overview of Products Specific Guidelines (July 2015)	1–4
4.25	Official Control Authority Batch Release (OCABR)/Official Batch Protocol Review (OBPR) for Immunological Veterinary Medicinal Products (IVMPs) (April 2014)	1–3

4.30	VBRN Procedures and Technical Guidelines – Preface (April 2014)	1–2
4.35	EU Administrative Procedure for a Harmonised Application of Article 81 for Official Batch Protocol Review of Immunological Veterinary Medicinal Products (November 2012)	1–11
4.40	EU Administrative Procedure for Application of Article 82 for Official Control Authority Batch Release of Immunological Veterinary Medicinal Products (November 2014)	1–13
4.45	Guidelines for EU Official Control Authority Batch Release (OCA-BR)/ EU Official Batch Protocol Review (OBPR) for Immunological Veterinary Medicinal Products IVMPs - Products Specific Guidelines (July 2015)	1–2

5 Richtlinien der Pharmazeutischen Inspektions-Convention/Co-Operation Scheme (PIC/S)

5.0	Pharmazeutische Inspektions-Convention (PIC), PIC Scheme (PIC/S), MRA und ACAA – Einführung	1–4
5.5	Pharmaceutical Inspection Co-Operation Scheme (PIC Scheme) - List of PIC/S Participating Authorities & Partners (July 2015)	1–7

6 Richtlinien der Organization for Economic Cooperation and Development (OECD) und sonstige GLP-Vorschriften

6.0	Organization for Economic Cooperation and Development (OECD) – Einführung	1–3
6.1	Grundsätze der Guten Laborpraxis (GLP) – GLP-Konsensdokument Nummer 1 (Neufassung Mai 1997)	1–2
6.2	Allgemeine Verwaltungsvorschrift zum Verfahren der behördlichen Überwachung der Einhaltung der Grundsätze der Guten Laborpraxis (ChemVwV-GLP) (November 2011)	1–16
6.3	Bekanntmachung eines Konsens-Dokuments der Bund-Länder-Arbeitsgruppe Gute Laborpraxis zur Archivierung und Aufbewahrung von Aufzeichnungen und Materialien (Mai 1998)	1–10
6.4	Bekanntmachung eines Konsens-Dokuments der Bund-Länder-Arbeitsgruppe Gute Laborpraxis (GLP) zum Thema „Gute Laborpraxis (GLP) und Datenverarbeitung“ (Oktober 1996)	1–22
6.20	Revised Guidance for the Conduct of Laboratory Inspections and Study Audits – Environment Monograph No. 111 – Guidance for GLP Monitoring Authorities (Guidance No. 3) (1995)	1–16
6.25	Leitfaden zur Harmonisierung des GLP-Überwachungsverfahrens in der Bundesrepublik Deutschland (April 2007)	1–9

6.30	Revised Guides for Compliance Monitoring Procedures for Good Laboratory Practice – Environment Monograph No. 110 – Guidance for GLP Monitoring Authorities (Nr. 2) (1995).....	1–16
6.40	Directive 2004/10/EC of the European Parliament and of the Council on the Harmonisation of Laws, Regulations and Administrative Provisions Relating to the Application of the Principles of Good Laboratory Practice and the Verification of their Applications for Tests on Chemical Substances (Codified Version) (February 2004)..	1–22
6.41	Directive 2004/9/EC of the European Parliament and of the Council on the Inspection and Verification of Good Laboratory Practice (GLP) (Codified version) (March 2009)	1–21
6.42	Qualitätssicherung und GLP – GLP-Konsensdokument Nummer 4 (überarbeitet, 1999).....	1–7
6.43	Einhaltung der GLP-Grundsätze durch Lieferanten – GLP-Konsensdokument Nummer 5 (überarbeitet, 1999).....	1–4
6.44	Anwendung der GLP-Grundsätze auf Freilandprüfungen – GLP-Konsensdokument Nummer 6 (überarbeitet, 1999).....	1–11
6.45	Anwendung der GLP-Grundsätze auf Kurzzeit-Prüfungen – GLP-Konsensdokument Nummer 7 (überarbeitet, 1999).....	1–11
6.46	Rolle und Verantwortlichkeiten des Prüfleiters bei GLP-Prüfungen – GLP-Konsensdokument Nummer 8 (überarbeitet, 1999).....	1–7
6.48	Anwendung der OECD GLP-Grundsätze auf Organisation und Management von Multi-Site-Prüfungen – Konsensdokument der Arbeitsgruppe GLP Nummer 13 (2002)	1–11
6.49	Anwendung der OECD GLP-Grundsätze auf <i>in vitro</i> Prüfungen – Beratungsdokument der Arbeitsgruppe GLP Nummer 14 (2004)	1–12
6.50	Einrichtung und Betrieb von Archiven in Übereinstimmung mit den Grundsätzen der Guten Laborpraxis – Beratungsdokument der Arbeitsgruppe GLP Nummer 15 (2007)	1–16

7 Richtlinien der Weltgesundheitsorganisation (WHO)

7.0	Weltgesundheitsorganisation (WHO) – Einführung	1
7.1	WHO Guidelines: Production, Quality Control, Inspections, Related Regulatory Standards - Overview (July 2015).....	1–7
7.2	WHO Recommendations, Guidelines and other Documents Related to the Manufacture and Quality Control of Biological Substances used in Medicine Overview (April 2014)	1–4
7.5	WHO - Good Manufacturing Practices for Pharmaceutical Products: Main Principles (2014)	1–48
7.10	WHO - Stability Testing of Active Pharmaceutical Ingredients and Finished Pharmaceutical Products (2009)	1–39

7.30	Anforderungen an die Entnahme, Verarbeitung und Qualitätskontrolle von Blut, Blutbestandteilen und Plasmabestandteilen (Anforderungen an biologische Substanzen Nr. 27, überarbeitet 1992) (Dezember 1995)	1–68
7.35	Guidelines for Assuring the Quality of Pharmaceutical and Biological Products Prepared by Recombinant DNA Technology (1992)	1–11
7.52	Good Manufacturing Practices: Supplementary Guidelines for the Manufacture of Pharmaceutical Excipients (1999).....	1–18

8 Richtlinien nationaler Fachgesellschaften

8.5	Empfehlungen zur Bewertung der Qualifikation von Prüfern und Geeignetheit von Prüfstellen durch Ethik-Kommissionen bei klinischen Prüfungen nach dem AMG (August 2009)	1–7
8.17	Richtlinie zur Gewinnung von Spenderhornhäuten und zum Führen einer Augenhornhautbank (BÄK – 2014)	1–37
8.30	Ergänzende Empfehlungen zu den Richtlinien zur Blutgruppenbestimmung und Bluttransfusion der Bundesärztekammer über Eigenblutspende und Eigenbluttransfusion (1994)	1–4
8.33	Richtlinie zur Herstellung und Anwendung von hämatopoetischen Stammzellzubereitungen (BÄK – 2014)	1–52
8.35	Richtlinien für die Herstellung von Plasma für besondere Zwecke (Hyperimmunplasma) (BÄK/PEI – 2000)	1–16

9 Richtlinien internationaler Fachgesellschaften

9.1	WMA Declaration of Helsinki – Ethical Principles for Medical Research Involving Human Subjects (World Medical Association) (2008)	1–6
------------	---	-----

10 Richtlinien sonstiger Herkunft

10.50	Verschleppung von Fütterungsarzneimitteln in Folgemischungen: Minimierung und Risikoverringerung – Hinweise für eine gute Herstellungspraxis (GHP) (DLG)	1–10
--------------	--	------

Register

I.	Sachregister	1–26
II.	Register EC/EU-Regulations und EC/EU-Directives allgemein nach Codes	1–3
III.	Register CHMP/CPMP Guidelines nach Codes.....	1–8
IV.	Register CHMP/ICH/CPMP/ICH Guidelines nach Codes	1–2
V.	Register ICH Guidelines nach Themen	1–5
VI.	Register CVMP Guidelines nach Codes	1–3
VII.	Register CVMP/VICH Guidelines nach Codes	1–2
VIII.	Register VICH Topics nach Themen	1–3
IX.	Register weitere EMA und EMEA Guidelines und andere Committees nach Codes.....	1
X.	Register Community Herbal Monographs und andere CHMP-Dokumente nach Codes	1–4
XI.	Register Community Herbal Monographs nach Arzneipflanzen	1–4